Norwegian Cruise mění cenotvorbu a nabízí levnější tarify dříve, aby podpořila předprodeje. Firma čeká v roce 2026 pokles čistých výnosů při konstantní měně asi o 5 %.
Key Takeaways Norwegian Cruise is using earlier, more competitive fares to build a stronger base of advance bookings.NCLH expects 2026 constant-currency net yields to fall about 5%, with steeper declines in the second half.Norwegian Cruise expects yield trends to improve through 2027 as booking and revenue changes take hold. Norwegian Cruise Line Holdings Ltd. (NCLH - Free Report) is revising its pricing strategy to build advance reservations and reduce exposure to discounting near departure. The company identified that fares on certain sailings remained too high too far ahead of departure, limiting early demand and leaving more inventory to sell closer to sailing.
Norwegian Cruise is adopting a “baseloading” approach, establishing more competitive fares earlier in the booking window to secure a stronger base of reservations. The objective is to maximize yield across the full booking cycle while maintaining pricing integrity closer to departure. The company also reported pricing adjustments on select 2027 sailings and already-open 2028 sailings. Newly opened Norwegian Cruise Line sailings for 2028 and beyond will follow this methodology from the outset.
Near-term revenue pressure nevertheless remains significant. Second-quarter 2026 constant-currency net yields declined 2.6% year over year. Advance bookings remain below the company’s optimal level amid marketing and demand-generation challenges, while elevated airfares have also pressured North American demand for European sailings. Norwegian Cruise expects constant-currency net yields to decline approximately 5% year over year in 2026, including declines of approximately 8.9% in the third quarter and 6.5% in the fourth quarter.
The revised approach could support a gradual recovery, with greater opportunity for later 2027 departures. Although implementation is underway, the extended booking cycle limits how quickly the changes can affect revenues. Norwegian Cruise expects first-half 2027 net yields to decline year over year, primarily because of first-quarter pressure. The company expects improvement as 2027 progresses, particularly in the second half, as the booking curve increasingly reflects its marketing, demand-generation and revenue-management changes.
Key Peers Show Stronger Advance DemandRoyal Caribbean Group (RCL - Free Report) is benefiting from strong demand and record pricing across its cruise portfolio. RCL reported that its booked position for 2026 and 2027 was in line with prior years at record prices. Early booking activity for 2027 was pacing ahead of historical levels, including for itineraries affected by geopolitical disruption in 2026. Royal Caribbean is using AI-driven revenue-management models to optimize pricing and yields across the booking cycle, supporting its efforts to capture demand while maintaining pricing strength.
Carnival Corporation (CCL - Free Report) is benefiting from a strong advance booking position as demand builds for future sailings. Approximately half of 2027 was already booked, with CCL’s occupancy and pricing at record levels. Demand remained broad based, including healthy bookings for peak summer European sailings. Booked occupancy and prices for 2028 were also ahead of the prior year, with the booking curve extending further out than ever at that point in the year. Although earlier booking disruptions continued to affect first-quarter 2027 expectations, Carnival’s advance demand supports its focus on managing the booking curve to support pricing and maximize revenues.
Key Takeaways Rigetti will supply PSC a 9-qubit Novera system for hybrid quantum-HPC testing, with deployment due in 2027.Rigetti sees 50-60 nanosecond gate speeds as key to complementing CPUs and GPUs in hybrid computing.Rigetti delivered two 9-qubit systems to commercial customers in 2026 as it pursues a 1,000-qubit roadmap. Rigetti Computing (RGTI - Free Report) is increasingly positioning its superconducting quantum computing technology for integration into high-performance computing (HPC) environments. A key development is the company's expanded collaboration with Hewlett Packard Enterprise (HPE - Free Report) and the Pittsburgh Supercomputing Center (“PSC”), under which Rigetti will provide a full 9-qubit Novera quantum computing system for PSC's TangleLab test bed. The system is expected to combine Rigetti's quantum processor, refrigeration and control infrastructure with Hewlett Packard’s HPC environment, allowing researchers and industry users to develop and test hybrid quantum-classical workloads. Rigetti expects the deployment in 2027. Management views the initiative as an important step toward moving its relationship with Hewlett Packard from early experimentation to commercially relevant quantum-enabled HPC solutions.
The hybrid computing opportunity is particularly relevant to Rigetti's strategy because the company believes its superconducting architecture can provide the processing speed needed to work alongside conventional CPUs and GPUs. Management cited gate speeds in the 50-60 nanosecond range and highlighted the potential for faster quantum processing to complement classical computing in workloads where quantum acceleration can reduce time to results or improve computational capabilities.
Beyond the collaboration with HPE, Rigetti is also seeing increasing interest from commercial organizations. The company delivered its first two 9-qubit systems in 2026 to commercial customers for research purposes. While these deployments do not yet represent production quantum workloads, the broader customer mix suggests that commercial engagement is beginning to develop alongside government and university demand.
With Rigetti continuing to improve the fidelity of its 108-qubit Cepheus system and pursuing a chiplet-based roadmap toward approximately 1,000 qubits, the company's strategy is increasingly centered on building the infrastructure and partnerships needed to support broader quantum adoption as the technology advances.
Peers UpdatesQuantum Computing Inc. (QUBT - Free Report) recently signed a three-year Framework Agreement with Hamad Bin Khalifa University in Qatar to collaborate on quantum computing, quantum sensing and quantum communications initiatives. The partnership will support joint academic research, executive education programs, industry-focused projects, quantum application development and co-marketing efforts aimed at accelerating quantum technology adoption across Qatar and beyond. The companies also plan to develop practical quantum solutions for real-world challenges while helping cultivate the next generation of quantum talent and leadership.
IonQ (IONQ - Free Report) recently announced a contract with Florida International University (“FIU”) to deliver and install a Superion 256-qubit trapped-ion quantum computer on the university's campus. The agreement marks the first sale and deployment of a Superion 256 system in Florida and establishes FIU as IonQ's flagship academic partner in the state, creating a hub for quantum research, education and workforce development. The on-campus deployment is expected to provide FIU's faculty, students and regional industry partners with direct access to advanced quantum computing capabilities, while FIU's engagement with federal agencies could support research initiatives spanning sensing, cryptography, commercialization and workforce development.
The partnership strengthens IonQ's presence in the academic quantum ecosystem and expands physical access to its hardware, potentially supporting broader adoption and talent development in the region.
Digital Realty uzavřela spolupráci s firmou Blackfuel, která v jejím datacentru BCN1 v Barceloně nasadí a rozšíří platformu pro AI inferenci. Projekt využívá kapalinou chlazenou infrastrukturu Dell AI Factory, AMD GPU a ServiceFabric.
Key Takeaways Digital Realty is helping Blackfuel deploy and scale its AI inference platform at BCN1 in Barcelona.Liquid-cooled Dell AI Factory infrastructure, AMD GPUs and ServiceFabric enable low-latency AI services.The deal supports DLR's strategy of combining capacity, power, cooling and interconnection for AI demand. Digital Realty (DLR - Free Report) is strengthening its artificial intelligence infrastructure capabilities through a collaboration with Blackfuel, which has selected the company’s BCN1 data center in Barcelona to deploy and scale its AI inference platform. The multi-megawatt deployment combines dedicated AI capacity, advanced cooling and private connectivity through Digital Realty’s ServiceFabric platform. The move also comes as peers such as Equinix (EQIX - Free Report) and Iron Mountain (IRM - Free Report) expand infrastructure designed for AI and accelerated computing workloads.
The deployment uses liquid-cooled Dell Technologies AI Factory infrastructure and AMD GPUs and integrates Blackfuel’s inference platform with ServiceFabric. This setup enables AI services to operate closer to enterprise applications, users and data, potentially reducing the need to move large volumes of information across public networks. This distributed, high-density infrastructure model is becoming increasingly important across the industry, with Equinix also investing in interconnected AI infrastructure and Iron Mountain adapting its data centers for accelerated computing.
Low-latency connectivity is an important part of the offering. Digital Realty notes that cutting Time-to-First-Token by 50 milliseconds could reduce completion times for agentic AI workflows involving 20-50 sequential inference calls by roughly 1-2.5 seconds compared with public Internet connectivity. At high volumes, such improvements could support greater efficiency and faster AI responses.
The collaboration also gives Blackfuel access to Digital Realty’s broader connected ecosystem. ServiceFabric spans more than 800 Digital Realty and third-party data centers worldwide, giving Blackfuel scope to expand its AI inference services beyond Barcelona while maintaining private connectivity to enterprise data and applications. Such connectivity capabilities could help Digital Realty differentiate its AI offering as Equinix continues to scale its own distributed AI ecosystem and Iron Mountain increases its focus on AI-ready data center capacity.
For Digital Realty, the deal reinforces its strategy of combining data center capacity, power, cooling and interconnection services to capture growing enterprise demand for AI infrastructure. With a global footprint of more than 300 facilities across 55-plus metros, the company appears well positioned to support customers seeking distributed, scalable AI deployments as inference workloads become more embedded in business applications.
AbbVie získala od FDA schválení pro Juvmo, lék užívaný jednou denně na Parkinsonovu chorobu, s plánovaným uvedením na trh v říjnu 2026. Spolu s Vyalev a Duopa má cílit na více než 5 miliard USD vrcholových tržeb.
Key Takeaways AbbVie adds Juvmo to its Parkinson's portfolio, offering standalone and combination treatment options.Juvmo is the first selective D1/D5 dopamine receptor agonist approved for Parkinson's disease.AbbVie expects its three Parkinson's therapies to represent a peak-sales opportunity above $5 billion. AbbVie (ABBV - Free Report) continues to expand its neuroscience franchise. The company recently secured FDA approval for Juvmo, a once-daily oral treatment for Parkinson’s disease (PD). A commercial launch is targeted for October 2026.
Juvmo Expands AbbVie’s Neuroscience PortfolioJuvmo is a potentially important addition to AbbVie’s PD portfolio, given its differentiated mechanism and broad treatment positioning. The drug is the first selective D1/D5 dopamine receptor agonist that can be used both as a standalone treatment and in combination with levodopa, the current standard of care for PD symptoms. This provides physicians another option for managing motor symptoms as the disease progresses and could help address the limitations associated with increasing reliance on levodopa.
Juvmo’s approval further expands AbbVie’s PD portfolio, which already includes Vyalev and Duopa. PD has emerged as a new pillar of the company’s neuroscience franchise, with management expecting the three therapies to collectively represent a peak-sales opportunity of more than $5 billion.
The neuroscience segment is one of AbbVie’s fastest-growing therapeutic areas. It now accounts for nearly a fifth of the company’s overall topline and generated $6.1 billion in revenues in the first half of 2026. Revenues from neuroscience drugs rose 22% year over year, driven by broad-based growth across the marketed portfolio. The company currently expects to record approximately $12.7 billion in neuroscience revenues in 2026.
The approval could also provide a commercial payoff from AbbVie’s acquisition of Cerevel Therapeutics for approximately $8.7 billion in 2024. The deal came under pressure after emraclidine, one of its key assets, failed in two registration-enabling phase II studies in schizophrenia, prompting AbbVie to record a $3.5 billion impairment charge. With Juvmo now approved, its commercial performance could become an important part of the value story behind the Cerevel acquisition.
ABBV’s Competition in the Neuroscience SpaceOther bigger players in the neuroscience space include Biogen (BIIB - Free Report) and Johnson & Johnson (JNJ - Free Report) .
As revenues from its legacy multiple sclerosis portfolio continue to decline, Biogen is increasingly focused on expanding its neuroscience business through newer therapies. Along with partner Eisai, Biogen markets Leqembi, one of the two FDA-approved treatments for AD. The company also markets Zurzuvae, the first FDA-approved oral treatment for postpartum depression.
JNJ's neuroscience business is anchored by the depression therapy Spravato and the long-acting antipsychotic Invega Sustenna. The company's acquisition of Intra-Cellular Therapies last year further strengthened its portfolio by adding Caplyta, an approved treatment for schizophrenia and bipolar depression.
Key Takeaways Walmart received about $2.9B in tariff refunds and increased rollbacks to more than 11,000.Target's $994M tariff refund benefit helped lift its second-quarter operating margin to 9.6%.Dollar General said tariff refunds added about 81 basis points to gross margin after reinvestments. Tariff refunds emerged as a meaningful earnings tailwind for major U.S. retailers in the second quarter, helping Walmart Inc. (WMT - Free Report) , Target Corporation (TGT - Free Report) and Dollar General Corporation (DG - Free Report) strengthen margins while giving them additional flexibility to invest in pricing, promotions and customer experience. Although each company approached the benefit differently, the refunds supported their broader strategies of protecting value-conscious shoppers and improving competitive positioning in an uncertain environment.
Walmart Channels Tariff Refunds Into Pricing ActionsWalmart saw a notable boost to profitability from tariff refunds while enabling the company to reinvest in customer-focused pricing initiatives. The company received substantially all of its eligible tariff refunds, totaling approximately $2.9 billion, or about 0.5% of annual U.S. net sales. The refunds contributed to stronger margins, with second-quarter consolidated gross profit rate expanding 96 basis points to 25.4%, driven primarily by Walmart U.S.
Walmart U.S. gross profit increased 9.4%, while gross profit rate improved 158 basis points to 29.4%, supported by tariff refunds and favorable business mix. The benefit also contributed to overall operating income growth, which increased 28.8% year over year, while adjusted operating income rose 17.4% on a constant-currency basis.
Management noted that tariff refunds provided an approximately 750-basis-point benefit to operating income growth in the quarter. Walmart directed the refunds toward customer experience and price leadership, particularly in grocery and general merchandise categories, increasing rollbacks to more than 11,000 during the period.
Target Gets a $994M Margin Boost From Tariff RefundsTarget also recorded a substantial tariff refund benefit during the second quarter. The company recognized $994 million in International Emergency Economic Powers Act tariff refunds as a reduction in the cost of sales. Second-quarter gross margin increased to 33.7%, including a 3.7 percentage-point benefit from tariff refunds. The refunds contributed $1.65 to adjusted earnings per share, while total tariff refund benefits contributed $752 million to net earnings. Excluding tariff refunds, adjusted earnings per share increased 20% year over year.
Tariff refunds also supported operating results. The second-quarter operating margin rate increased to 9.6% from 5.2% a year ago, with tariff refunds accounting for 3.7 percentage points of the improvement. Excluding the refund impact, the operating margin rate was approximately 70 basis points higher than the prior year. The company expects its fiscal 2026 operating margin to include about 90 basis points of benefit from second-quarter tariff refunds.
Beyond improving reported profitability, Target used its stronger financial position to continue investing in value initiatives. Management highlighted that the company lowered prices on more than 10,000 frequently purchased items over the past year while continuing to invest in newness, convenience and the shopping experience. The company’s second-quarter results also showed broad-based sales strength, including growth across all six core merchandising categories and increased digital sales.
Dollar General Directs Tariff Refunds Toward Customer ValueDollar General benefited from tariff refunds in the second quarter, supporting gross margin expansion and improved profitability. The company reported that gross profit as a percentage of sales increased 127 basis points year over year to 32.6%, driven by tariff refunds, lower LIFO provisions and reduced distribution costs. After considering related reinvestments, tariff refunds contributed approximately 81 basis points to gross margin expansion.
The benefit also supported operating performance, with operating profit rising 29.2% year over year to $769.2 million and operating margin expanding 126 basis points to 6.8%. Dollar General estimated that tariff refunds, after reinvestments, contributed about 66 basis points to operating margin growth. Adjusted earnings per share increased 33% to $2.48, including an estimated 25 cents benefit from tariff refunds.
The company used the refund benefits to support customer-focused initiatives, including targeted promotions, lower everyday prices and increased marketing investments. Dollar General received the majority of expected tariff refunds during the quarter and does not expect a material impact from refunds after reinvestments in the second half of fiscal 2026.
Final WordsTariff refunds provided Walmart, Target and Dollar General with temporary financial support that strengthened near-term margins and earnings. The companies used the benefit strategically, primarily through price investments and customer-focused initiatives, to reinforce their value propositions in an increasingly competitive retail landscape.
Lemonade zvýšila pojistné v platnosti o 32,5 % meziročně na 1,43 mld. USD a už 11. čtvrtletí po sobě zrychluje růst. Firma čeká ziskovost na úrovni EBITDA do 4. čtvrtletí 2026.
Key Takeaways Lemonade's in-force premium rose 32.5% year over year to $1.43 billion, extending accelerating growth.LMND's AI model is improving underwriting, claims processing and operating efficiency as loss ratios decline.Lemonade expects EBITDA profitability by Q4 2026, with positive free cash flow & $1.2B in cash & investments. Lemonade Inc.’s (LMND - Free Report) robust premium growth, improving underwriting results and steady progress toward profitability position it well for sustained growth. Rising in-force premium, increasing multi-policy adoption and continued expansion of Lemonade Auto and its AI-powered platform are supporting revenue growth while enhancing operating efficiency.
The company surpassed earnings estimates in each of the last four quarters, with the average surprise being 19.35%.
Factors in Favor of LMNDLemonade’s AI-driven operating model continues to strengthen underwriting, pricing, claims processing and customer service while supporting a scalable and cost-efficient business model. Operating efficiency is improving, with in-force premium per customer rising 8% in the second quarter of 2026. Underwriting trends also remain favorable, as the gross loss ratio declined despite losses related to winter storms. Disciplined underwriting and favorable prior-year reserve development contributed to a 76% increase in second-quarter gross profit, supporting the company’s progress toward sustained profitability.
Pet Insurance and Lemonade Auto continue to deliver strong growth, while increasing multi-policy adoption enhances customer retention and lifetime value. The company’s multi-product strategy also creates cross-selling opportunities and supports recurring premium growth. Management forecasts 9% revenue growth for the second quarter and 65% growth for full-year 2026.
Lemonade’s in-force premium reached $1.43 billion, increasing about 32.5% year over year and marking the 11th consecutive quarter of accelerating growth. The momentum reflects customer expansion, higher premiums per customer and the scalability of its AI- and automation-driven platform. Management has set a long-term target of increasing in-force premium to $10 billion.
The company’s reinsurance strategy remains another key strength, transferring a significant portion of claims risk to partners and helping reduce earnings volatility. Strong premium growth, combined with a lower reinsurance ceding rate, allows Lemonade to retain a greater share of premiums and supports revenue growth.
Although profitability remains a work in progress, margins are improving and free cash flow has turned positive. Management expects EBITDA profitability by the fourth quarter of 2026. Lemonade ended the second quarter with approximately $1.2 billion in cash and investments, providing ample financial flexibility to support continued growth and investment.
Risks for LMNDLemonade’s results remain vulnerable to catastrophe-related losses. Although weather-related claims were manageable in the second quarter, severe storms, hurricanes, wildfires and other catastrophic events could significantly increase claims costs, pressure underwriting margins and contribute to earnings volatility.
The company also continues to invest heavily in customer acquisition, with sales and marketing expenses increasing more than 30% year over year in the second quarter of 2026. Elevated spending could weigh on margins if customer acquisition and retention do not generate sufficient returns. While marketing efficiency remains healthy, sustaining strong returns on acquisition spending will be crucial to Lemonade’s long-term profitability.
ConclusionLemonade is well-positioned for long-term growth, supported by strong premium expansion, an AI-driven operating model and improving profitability. Its diversified product portfolio, disciplined underwriting and reinsurance strategy strengthen its competitive position.
Yet, Lemonade remains exposed to catastrophe-related losses, which could raise claims costs, pressure underwriting margins and increase earnings volatility. In addition, elevated customer acquisition spending could weigh on profitability if acquisition and retention efforts fail to generate sufficient returns.
Other InsurersOther players from insurance industry include NMI Holdings Inc. (NMIH - Free Report) , Palomar Holdings, Inc. (PLMR - Free Report) and Arch Capital Group Ltd. (ACGL - Free Report) .
NMI Holdings’ earnings surpassed estimates in three of the last four quarters and matched in one, the average surprise being 3.82%.
NMI Holdings is well-poised for growth on new primary insurance written, direct primary insurance in force and a better risk-based capital ratio. Its mortgage insurance portfolio is expected to create a strong foundation for future earnings. The mortgage insurer should continue to gain from a strong mortgage origination market and increased private mortgage insurance penetration rates.
Palomar’s earnings surpassed estimates in each of the last four quarters, the average surprise being 13.04%.
Palomar is poised to gain from the increased volume of policies written across the lines of business, strong retention rates, strategic expansion of products’ geographic and distribution footprint and new partnerships. PLMR should benefit from its solid product portfolio as well as geographic expansion and rate increases. Net investment income is expected to grow on the back of a higher average balance of investments. PLMR increased the adjusted net income guidance from $262-$ 278 million to $270-$280 million.
Arch Capital’s earnings surpassed estimates in each of the last four quarters, the average surprise being 12.75%.
Arch Capital boasts a strong product portfolio and has a solid track record of premium growth. Premiums should benefit from new business opportunities, rate increases, growth in existing accounts and growth in Australian single-premium mortgage insurance. A solid capital position shields it from market volatility.
Palantir oznámil devátý po sobě jdoucí ziskový odhad na akcii (EPS) a tržby 1,935 miliardy USD, což je meziročně o 92,83 % více. Firma zároveň zvýšila celoroční výhled tržeb na 8,150 až 8,158 miliardy USD.
Palantir just posted its ninth consecutive earnings beat and revenue growth that left Wall Street scrambling to revise its models upward, yet the stock still sits 9% below its peak. Whether that gap is an opportunity or a warning depends…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Our 24/7 Wall St. price target for Palantir Technologies (NASDAQ:PLTR | PLTR Price Prediction) is $202.14 over the next 12 months. With shares at $188.77, that means 7.1% upside. Our model rates Palantir a buy with high confidence.
24/7 Wall St. Price Target Summary Metric Value Current Price $188.77 Price Target from 24/7 Wall St. $202.14 Upside 7.1% Recommendation BUY Confidence Level 90% That target sits above the Wall Street consensus of $195.57. Management raised full-year revenue guidance to $8.150 billion to $8.158 billion, representing 82% growth. The question is whether growth can outrun a valuation that already prices in significant upside.
A Second-Quarter Earnings Beat Sparked a Sharp Rebound Palantir traded near $123.06 on August 1. A week later it was at $172.01, after the August 3 earnings report. Shares are up 6.2% year to date and 1.28% over the past month, but down 1.57% this week. The stock sits 9% below its 52-week high of $207.52 and 77% higher than its low of $106.37.
Second-quarter EPS of $0.41 exceeded the $0.28 estimate, Palantir’s ninth consecutive beat. Revenue reached $1.935 billion, up 92.83%. U.S. commercial revenue grew 149% to $764 million. CEO Alex Karp called the quarter “otherworldly,” pointing to a Rule of 40 score of 155%.
Why Bulls See $219 and Beyond In the forward pipeline, U.S. commercial total contract value rose 153% to $2.132 billion, and remaining deal value climbed 124% to $6.238 billion.
The 2027 EPS consensus has risen to $2.3267 from $2.0821 90 days ago, with 26 upward revisions and zero cuts in 30 days. If AI sovereignty demand speeds up, the bull case reaches $219.29.
A Premium Valuation Leaves Little Room for a Stumble Palantir trades at 160x trailing earnings and 73x sales. Its government contracts can be ended for convenience, and stock-based compensation reached $265 million last quarter. Our bear case is $170.22. Even so, GAAP operating margin reached 47% after those compensation costs, so profitability already covers the dilution.
Palantir Outgrows CrowdStrike, Snowflake and ServiceNow CrowdStrike (NASDAQ:CRWD) is in the same software-infrastructure industry and also carries a premium for AI exposure. The stock changes hands at 208x forward earnings on 25.8% revenue growth.
Also competing with Palantir for enterprise data and AI workloads is Snowflake (NYSE:SNOW), yet its 169x forward multiple comes with 35.1% growth.
ServiceNow (NYSE:NOW) is the value contrast, trading at 28x forward earnings on 24% growth.
Company Forward P/E Quarterly Revenue Growth YoY Palantir 85x 92.8% CrowdStrike 208x 25.8% Snowflake 169x 35.1% ServiceNow 28x 24% Palantir is growing several times faster than its high-multiple peers and trades at a lower forward multiple than both. Measured against that group, our 24/7 Wall St. price target looks reasonable and even conservative.
Palantir Earns Its Premium, and the Upside Is Still Building The 24/7 Wall St. price target of $202.14 comes with a buy rating and 90% confidence. What tips the scale is the steady stream of upward earnings revisions.
The case gets stronger if U.S. commercial growth stays above 100% and the third quarter beats the $2.160 billion to $2.164 billion revenue guide. It weakens if deal momentum slows while the multiple stays extended. For now, growth is exceeding the valuation.
Palantir Price Prediction 2026-2030 Looking further ahead, here is where our model projects Palantir could trade at each year’s end, assuming current growth trends and market conditions hold.
Year Price Target from 24/7 Wall St. 2026 $190.18 2027 $204.33 2028 $212.81 2029 $236.20 2030 $251.97 Palantir’s continued execution on its AIP-led commercial expansion supports these projections. Sovereign AI demand could drove results well above this path, while a drop in government spending could pull them below it.
Contact [email protected] for any questions or corrections.
Palantir vykázal nejrychlejší růst tržeb v historii společnosti: tržby vzrostly o 92,83 % na 1,935 miliardy USD a celoroční výhled tržeb zvýšil už podruhé za sebou.
Palantir just posted numbers that left Wall Street scrambling to justify its own cautious price targets, and the real question is whether the valuation ceiling everyone keeps citing is about to become a floor.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The 24/7 Wall St. price target for Palantir (NASDAQ:PLTR | PLTR Price Prediction) is $202.08 over the next 12 months. That implies 8.08% upside from the model’s $186.97 starting price. Our model gives the stock a high-confidence buy rating.
24/7 Wall St. Price Target Summary Metric Value Current Price $186.97 Price Target from 24/7 Wall St. $202.08 Upside/Downside 8.08% Recommendation BUY Confidence Level 90% Palantir posted the fastest revenue growth in its history and raised full-year guidance for the second straight quarter. The upside in our target is modest because the valuation already reflects much of that momentum. The growth path is long enough that Palantir can keep compounding well past our 12-month window.
A 93% Growth Quarter Restarted Palantir’s Rally Shares rose 2.36% over the past week and are up 6.53% year to date at $189.36 this morning. The stock is 8.8% below its $207.52 52-week high and 78% above its $106.37 low.
Revenue grew 92.83% to $1.935 billion. EPS came in at $0.41 against a $0.28 estimate, which made it the ninth consecutive beat. Full-year revenue guidance now is at $8.150 billion to $8.158 billion, up from the $7.182 billion to $7.198 billion range Palantir gave in February. PwC also expanded its strategic alliance with Palantir on September 3 to help organizations scale enterprise AI.
Why Bulls See $219 and Beyond Net dollar retention reached 157%, and total remaining deal value hit $13.1 billion, up 83%. Palantir closed 73 deals worth $10 million or more in the quarter. CEO Alex Karp said, “I am driving the business to grow at a rate equal to or above what we have in U.S. commercial for the next 18 months.”
The adjusted operating margin reached 62%, and Palantir guides for $4.50 billion to $4.70 billion in adjusted free cash flow for the year. 21 analysts rate the stock a buy or strong buy. Under the most optimistic scenario, shares reach $219.27.
Valuation and Dilution Could Cap the Upside Shares trade at 159x trailing earnings and 85x forward earnings. Stock-based compensation was $265 million in Q2, and gains on Palantir’s SpaceX stake added $0.03 to GAAP EPS. Government contracts terminable for convenience pose a risk.
Two analysts rate the stock a sell or strong sell, and the downside scenario points to $170.18. Q2 free cash flow of $1.220 billion far exceeded stock-based compensation, while adjusted expenses rose 37% due to AI platform investment and technical hiring.
How Palantir Stacks Up Against Snowflake and MongoDB Snowflake (NYSE:SNOW) competes for enterprise AI data budgets with 35.09% revenue growth but a GAAP operating loss of $263 million.
MongoDB (NASDAQ:MDB) sells AI-ready databases with 30.5% revenue growth.
Company Latest Quarter Revenue Growth Adjusted Operating Margin Palantir 92.83% 62% Snowflake 35.09% 15.3% MongoDB 30.5% 24% Palantir is growing close to three times as fast as either peer and at far higher margins. Against that group, the 24/7 Wall St. price target looks reasonable, and arguably conservative.
Palantir’s Growth Tips the Scale Toward Our Buy Rating The 24/7 Wall St. price target of $202.08 carries a buy rating and 90% confidence. What tips the scale is Palantir’s ability to keep speeding up growth while margins expand.
I would view shares more favorably if U.S. commercial growth holds above 100% into 2027. I would grow more cautious if the pace of deal closings slows while the stock still trades at 85x forward earnings.
Palantir’s profile, hypergrowth at scale with expanding margins, mirrors the early traits of past tech giants. We collected those signs in a free playbook you can grab here.
Here is where our model projects Palantir could trade if current growth trends and market conditions hold.
Year Price Target from 24/7 Wall St. 2026 $185.07 2027 $202.08 2028 $218.13 2029 $233.16 2030 $237.90 Contact [email protected] for any questions or corrections.
Bristol Myers Squibb oznámila, že tržby Camzyosu v první polovině roku 2026 meziročně vzrostly o 74 % na 729 milionů USD. FDA navíc rozšířila jeho použití i u pediatrických pacientů s oHCM.
Key Takeaways BMY's Camzyos sales surged 74% year over year to $729 million in the first half of 2026.Camzyos now has the broadest indication among cardiac myosin inhibitors, including pediatric oHCM patients.CYTK's Myqorzo and EWTX's EDG-7500 could increase competitive pressure on BMY's cardiovascular franchise. Bristol Myers Squibb (BMY - Free Report) is banking on label expansion of existing drugs and approval of new drugs to further propel its growth portfolio.
Camzyos (mavacamten) is one of the key drugs in this product portfolio. The drug is currently approved in the United States for adults with symptomatic New York Heart Association (“NYHA”) class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve symptoms and functional capacity.
It continued to gain traction in the targeted market in the first half of 2026, supported by growing demand and increased adoption among eligible patients. Sales of the drug surged 74% year over year to $729 million in the first half.
The FDA recently approved the drug for the treatment of symptomatic oHCM to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more.
Consequently, Camzyos now has the broadest indication of any cardiac myosin inhibitor (CMI). It is the only FDA-approved therapy for the treatment of oHCM in a pediatric population.
The approval was based on positive results of phase III SCOUT-HCM study, building on the extensive clinical evidence for Camzyos in adults with oHCM.
For Bristol Myers, continued growth from Camzyos is particularly important as the company works to offset revenue pressures from patent expirations affecting legacy drugs.
BMY’s cardiovascular portfolio also includes blood thinner medicine Eliquis, for which BMY has a worldwide co-development and co-commercialization agreement with pharma giant Pfizer. Eliquis remains one of the biggest contributors to the company’s top line.
Bristol Myers’ cardiovascular pipeline includes milvexian, an investigational oral, highly selective factor XIa (FXIa) inhibitor.
The candidate, developed in collaboration with Johnson & Johnson, is being evaluated in two late-stage studies — Librexia AF for atrial fibrillation (AF) and Librexia STROKE for secondary stroke prevention (SSP).
Data from the LIBREXIA-STROKE study is expected in 2026, while results from the Librexia AF study are expected in the first quarter of 2027.
However, the cardiovascular portfolio suffered a setback in late 2025 after the company decided to discontinue the late-stage Librexia study on milvexian.
BMY and partner Johnson & Johnson were evaluating the efficacy and safety of milvexian when added to standard of care (conventional antiplatelet therapy) for patients following an acute coronary syndrome event.
Both companies decided to discontinue the phase III Librexia ACS study following a preplanned interim analysis by the Independent Data Monitoring Committee, which determined that the study was unlikely to meet its primary efficacy endpoint.
Competition for BMY’s CamzyosCytokinetics (CYTK - Free Report) became a direct competitor to Bristol Myers Squibb in the oHCM market after securing FDA approval for Myqorzo (aficamten) in December 2025. As Cytokinetics’ first approved product, Myqorzo marks its transition to a commercial-stage company and gives investors a new challenger in the CMI market.
While Camzyos benefits from an established commercial presence and extensive clinical and real-world data, Myqorzo’s initial uptake has been encouraging and could gradually increase competitive pressure on BMY’s cardiovascular franchise.
Cytokinetics recently announced the launch of ASPEN-HCM, a prospective, multicenter observational study designed to evaluate the real-world use of Myqorzo in adults with symptomatic oHCM.
A potential competitor is Edgewise Therapeutics, Inc. (EWTX - Free Report) , which is advancing a cardiovascular pipeline targeting HCM, heart failure, and other cardiovascular and cardiometabolic conditions.
EWTX’s lead candidate, EDG-7500, is a novel, oral, selective cardiac sarcomere modulator currently being studied in a multi-part phase II study in patients with oHCM and nHCM, with a phase III program targeted to be initiated in the fourth quarter of 2026.
EWTX’s pipeline also includes EDG-15400 for heart failure. The company expects to initiate a phase II study on EDG-15400 in participants with heart failure with preserved ejection fraction.
Micron má už přes 75 % produkce pro rok 2027 předem zajištěno a drží 32 mld. USD v zákaznických zálohách a smlouvách take-or-pay. Firma má do prosince 2026 dosáhnout cílové hotovosti, což otevře prostor pro nové odkupy akcií.
SummaryMicron Technology is rated Buy, trading at just 6.8x forward earnings despite robust demand signals and a 379% YoY revenue surge to $54.2B.Over 75% of MU's 2027 output is already committed, with $32B in customer deposits and strategic take-or-pay contracts providing margin floors above historical peaks.MU is set to reach its cash target by December 2026, enabling a substantial new buyback authorization as the CHIPS Act cap lifts, with potential for a 7–8% buyback yield.Key risk: if major customers broadly cut memory per server, 2028 pricing power could erode, but current demand and prepayments suggest the rally has more runway.62 Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of MU either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Intuitive Surgical čelí v Číně slabým výběrovým řízením a cenovému tlaku, když ve čtvrtletí umístila jen dva systémy. Růst v Indii a Japonsku to částečně vyvažuje; v Japonsku umístila 25 systémů oproti 15 před rokem.
Key Takeaways ISRG faces China pressure from weak tenders, domestic competition and pricing, with just two systems placed.ISRG gained da Vinci 5 clearance in India, supporting demand across a broad range of procedures.ISRG placed 25 systems in Japan versus 15 a year ago as new reimbursement policies supported robotic use. Intuitive Surgical’s (ISRG - Free Report) geographical growth story is becoming increasingly diversified, with strong momentum in India and improving conditions in Japan helping counterbalance challenges in China. In the second quarter, international da Vinci procedures increased 20%, while Europe and Asia delivered 20% growth each.
China remains the primary regional headwind for ISRG. Management cited lower tender activity, increased domestic robotic competition and policy-driven pricing pressure, alongside changes in charge codes and the 15th Five-Year Plan quota process. System placements were particularly weak, with only two da Vinci systems placed in China during the quarter. Da Vinci 5 is yet to receive clearance in mainland China.
India, meanwhile, is emerging as an important growth market. Management described another strong quarter, with momentum across a broad range of procedures. The clearance of da Vinci 5 in India during the quarter should expand Intuitive Surgical’s ability to address demand with its latest-generation platform. International procedure growth also highlighted India as one of the markets delivering strong results.
Japan offers another potential growth avenue. Policies effective June 1 expanded reimbursement to additional robotic procedures and introduced economic incentives for higher utilization. Intuitive Surgical placed 25 systems in Japan versus 15 a year earlier, while management said recent reimbursement decisions were encouraging. However, adoption is expected to progress gradually, given training requirements and ongoing financial challenges.
China remains a meaningful uncertainty, but India, Japan and other international markets provide diversification. Intuitive Surgical maintained its 2026 da Vinci procedure growth outlook of 13.5-15.5%, with international procedures outside urology among its primary growth drivers.
Peer UpdatesBoston Scientific (BSX - Free Report) is broadening its Asian growth base. Unlike ISRG, China remains a key international market for Boston Scientific. Asia-Pacific revenues increased 11% operationally, led by double-digit growth in Japan, China and Korea, with Interventional Cardiology, Electrophysiology and WATCHMAN driving regional performance.
International EP sales increased 23%, and management expects approximately 20% international EP growth for full-year 2026, providing an important growth avenue outside any single market. Japan represents a clearly identified diversification opportunity within Asia for Boston Scientific.
Medtronic (MDT - Free Report) is also expanding in Asia, primarily through Japan. International revenues grew 12%, supported by several businesses delivering double-digit international growth. Within Cardiac Ablation Solutions, Medtronic management highlighted geographic expansion, noting that Sphere-9 was launching in Japan, alongside continued ecosystem development across mapping, ICE technology and ablation. Medtronic is also expanding its international robotics portfolio through a strategic investment and distribution agreement for Cornerstone’s Sentire Surgical System in select markets outside the United States.
BlackBerry snížila výhled tržeb v segmentu Secure Communications pro FY27 na 260–270 milionů USD z 270–280 milionů USD kvůli nejistotě ohledně načasování vládních zakázek. Ve 2. čtvrtletí tržby segmentu vzrostly o 2 % na 61 milionů USD a ARR o 4 % na zhruba 221 milionů USD.
Key Takeaways BlackBerry cut FY27 Secure Communications revenue guidance to $260-$270 million from $270-$280 million.About 80% of the business is backed by ARR, while larger government deals drive timing uncertainty.Secure Communications Q2 revenues rose 2% to $61 million, while ARR increased 4% to about $221 million. BlackBerry (BB - Free Report) entered the second half of fiscal 2027 with a cautious outlook for its Secure Communications business, despite maintaining a relatively stable recurring-revenue base and continuing to see customer activity across key government and regulated markets.
Following the first quarter, BlackBerry had projected fiscal 2027 Secure Communications revenues in the range of $270-$280 million. In its latest update, the company lowered that range to $260-$270 million, while guiding adjusted EBITDA to $50-$58 million.
Management said it was taking a cautious view on the timing of government opportunities amid broader geopolitical and trade uncertainty, including Canada-U.S. tensions. However, management added that BlackBerry has not seen “anything material arising from this issue” and has not observed a “slowdown in pipeline generation outside of North America”.
In the fiscal second quarter, Secure Communications revenues rose 2% year over year to $61 million. Segment adjusted gross margin fell 500 basis points to 61%, reflecting lower-margin Secusmart device revenues. Adjusted EBITDA was $8 million, down 18%, with a 13% margin. Annual recurring revenues reached approximately $221 million, up 4%, while dollar-based net retention was 91%.
First-half Secure Communications revenues rose 13% year over year, supported by renewals and expansions across the United States, Canada, Europe, Asia and the Middle East.
Management noted that about 80% of the business is supported by ARR. However, the key uncertainty lies in the roughly 20% of the revenue outlook tied to larger government deals. Management said larger government opportunities can create quarter-to-quarter variability as these have long sales cycles.
Let’s Look at BB’s PeersIn the broader cybersecurity market, BlackBerry operates alongside several leading names, including CrowdStrike Holdings (CRWD - Free Report) , Palo Alto Networks (PANW - Free Report) and Motorola Solutions (MSI - Free Report) .
While BlackBerry focuses on encrypted communications and sovereign-grade infrastructure, CrowdStrike is a leading pure-play cybersecurity vendor. Revenues for the second quarter of fiscal 2027 stood at $1.47 billion, increasing 26% year over year. CrowdStrike’s growth is being fueled by rising AI-security demand, Falcon Flex adoption and momentum across next-gen SIEM and AIDR adoption. For fiscal 2027, CrowdStrike’s revenues are now projected between $5.991 billion and $6.011 billion, with ARR of $6.603 billion to $6.612 billion.
Palo Alto Networks’ fiscal fourth-quarter revenues surged 34% to $3.41 billion, while remaining performance obligations reached $21.2 billion, up 34%. Performance was driven by broad-based strength across Network and AI Security, XSIAM momentum and contributions from CyberArk and Chronosphere acquisitions. Palo Alto Networks expects fiscal 2027 Network & AI Security revenues to grow in the low double digits. Cortex revenues is projected to rise about 30% and Idira revenues are expected to reach approximately $1.5 billion.
Motorola, through its Software and Services segment, offers a wide range of services and software to government, public safety and commercial communication networks. Services include offerings such as repair, technical support and maintenance, along with monitoring, software updates and cybersecurity services. Motorola’s second-quarter revenues rose 13% year over year, while Software and Services revenues increased 10%.
Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only seen from two companies in history.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Eli Lilly (NYSE:LLY | LLY Price Prediction) trades at $1,184.92, which gives it a market value of about $1.057 trillion. The 24/7 Wall St. price target for Eli Lilly is $1,401.42 over the next 12 months. That means 18.27% upside and earns a high-confidence buy rating from our model.
24/7 Wall St. Price Target Summary Metric Value Current Price $1,184.92 Price Target from 24/7 Wall St. $1,401.42 Upside/Downside 18.27% Recommendation BUY Confidence Level 90% If shares hit our target, Lilly would be worth about $1.25 trillion. A $2 trillion valuation would take a share price near $2,243 on today’s share count. It sits above our base-case 2031 milestone of $2,000.56, so the headline goal depends on the pipeline outperforming.
A Blowout Q2 and Fresh Retatrutide Data Keep Lilly Near Its Highs Shares have gained 1.21% over the past week, 10.74% year to date and 64.04% over the past year. The stock sits 8.3% below its 52-week high of $1,292.65.
Second-quarter revenue of $22.97 billion rose 47.7% and beat the $20.69 billion consensus. EPS of $8.38 exceeded the $6.58 estimate even after $3.03 of acquired IPR&D charges. Management also raised full-year revenue guidance to $85 billion to $87 billion.
September added to the momentum. The FDA approved Onswik, a once-weekly insulin, on September 24. At the EASD meeting, Lilly presented new retatrutide results and a comparison in which Foundayo beat oral semaglutide.
Why Bulls See $1,460 and Beyond Lilly plans to file retatrutide in Q1 2027, after trial patients lost up to 71.2 lbs. Foundayo prescribers rose to about 36,000, and a global rollout is planned for 2027.
Medicare’s GLP-1 Bridge Program opened coverage to 20 million eligible Americans. Analysts expect 2027 EPS of $47.5425, up from $44.4568 90 days ago. The consensus target is $1,328.83. Our bull case hits $1,460.67, or 23.27% upside.
Falling GLP-1 Prices Could Stall the Rally Excluding rebate adjustments, U.S. prices fell 9% last quarter. Mounjaro and Zepbound brought in $14.9 billion, most of Lilly’s revenue. Generic semaglutide is now on sale in India and Brazil, and the retatrutide filing pathway faces litigation. One analyst rates the stock Sell and another Strong Sell.
The bear case of $1,191.31 suggests little gain from here. On the other side, the IPR&D charges come from acquisitions and do not repeat. Volume growth also more than made up for lower prices.
Lilly Earns Its Premium Over Novo Nordisk, Merck and AbbVie Novo Nordisk (NYSE:NVO) is Lilly’s direct GLP-1 rival. It trades at 12x forward earnings, but quarterly earnings fell 20.6%. Merck (NYSE:MRK) shows what a mature pharma multiple looks like. AbbVie (NYSE:ABBV) competes with Lilly in immunology.
Company Forward P/E Quarterly Revenue Growth Eli Lilly 24x 47.7% Novo Nordisk 12x 2.1% Merck 15x 5.1% AbbVie 16x 10.2% Lilly is growing revenue several times faster than any of these peers. That growth supports its higher multiple and makes the 24/7 Wall St. price target look reasonable.
Lilly Still Has Room to Run The 24/7 Wall St. price target of $1,401.42 carries a buy rating and high confidence. What tips the scale is rising earnings estimates.
Bulls stay in control if volume continues outpacing price cuts and retatrutide files on schedule. Bears take over if U.S. price declines grow faster than prescriptions. Right now, the growth numbers favor the bulls.
Here is where our model projects Lilly trading if current growth trends and market conditions hold.
Year Price Target from 24/7 Wall St. 2026 $1,233.89 2027 $1,406.11 2028 $1,583.87 2029 $1,748.51 2030 $1,889.79 These projections assume Lilly continues executing its current strategy. Retatrutide’s approval or faster GLP-1 price erosion could drive results well above or below this path.
Contact [email protected] for any questions or corrections.
Morgan Stanley těží z vyšších sazeb: tržby Wealth Managementu v první polovině 2026 vzrostly o 15 % na 17,4 miliardy USD a čistý úrokový výnos o 16 % na 4,4 miliardy USD.
Key Takeaways Morgan Stanley's Wealth Management revenues rose 15% to $17.4 billion in the first half of 2026.MS could see NII trend higher as wider spreads, loan growth and deposit mix support interest income.Higher deposit costs, softer borrowing and market pressure could weigh on Morgan Stanley's fee revenues. The Federal Reserve’s September rate hike could provide another earnings tailwind for Morgan Stanley’s (MS - Free Report) Wealth Management business. The 25-basis-point increase in the federal funds target range to 3.75-4.00% may support yields on client cash and lending balances, potentially lifting net interest income (NII).
Morgan Stanley enters the higher-rate backdrop from a position of strength. Wealth Management revenues rose 15% year over year to $17.4 billion in the first half of 2026, while NII increased 16% to $4.4 billion. Higher average sweep deposits and lending growth were key drivers. The segment’s fee-based engine also remained strong. Asset management revenues climbed 17% to $10.3 billion, supported by favorable markets and solid fee-based flows. Net new assets reached a record $266.5 billion during the period, expanding the base for recurring advisory and asset-management revenues.
The latest rate increase is expected to reinforce the NII trajectory. Even before the Fed’s September move, Morgan Stanley had expected a modest sequential rise in Wealth Management NII in the third quarter, with further improvement supported by loan growth and deposit mix. Higher short-term rates are likely to add incremental upside if client cash balances remain stable and deposit repricing stays manageable.
However, the benefits are unlikely to be entirely one-sided. Higher deposit costs could limit spread expansion, particularly if competition for client cash intensifies. At the same time, persistently elevated rates could soften lending demand and pressure equity and bond valuations. That would matter for Morgan Stanley because a sizable portion of Wealth Management revenues is tied to asset levels and client activity. Weaker markets could slow asset-based fees, while lower transaction volumes could weigh on transactional revenues.
Higher rates add another potential support to Morgan Stanley’s Wealth Management earnings, but the durability of the benefit will depend on the interaction between NII growth and fee-revenue trends. Continued asset inflows, stable deposits and healthy lending activity could help sustain segment momentum, while rising funding costs and softer markets remain key offsets.
How JPMorgan and Goldman Sachs Stack UpJPMorgan’s (JPM - Free Report) Asset & Wealth Management business is also positioned to benefit from resilient deposit and lending activity amid higher rates. First-half revenues jumped 15% year over year to $13.2 billion, while average loans rose 16% and deposits increased 4%. Assets under management reached $5.14 trillion, up 18%. Higher rates could support spread income, though more attractive cash yields may encourage clients to shift deposits toward higher-yielding investment products and potentially restrain borrowing.
Goldman Sachs (GS - Free Report) presents a somewhat different setup. Its Asset & Wealth Management revenues increased 15% year over year to $8.7 billion in the first half of 2026, driven by higher management fees and investment revenues. However, private banking and lending revenues declined because of a lower net interest margin related to Marcus deposits. A higher-rate environment will likely help stabilize lending spreads, but elevated funding costs remain a key variable.
Broadcom dnes vzrostl o více než 2,7 %, protože banky připravují 60 miliard USD na financování infrastruktury pro AI čipy. Z toho 42 miliard USD má připadnout na dluh třídy A a 18 miliard USD na dluh třídy B. UBS zároveň zopakovala doporučení Buy a cílovou cenu 470 USD.
Broadcom stock AVGO gained more than 2.7% in trading on Friday as Wall Street banks prepared a potential $60 billion financing package for artificial intelligence chip infrastructure.
Bloomberg News reported that banks in Broadcom Inc.'s syndicate are preparing to market $42 billion of Class A senior-secured debt, while Blackstone is leading an additional $18 billion tranche of Class B junior debt.
The financing has been taking shape for several weeks, according to people familiar with the matter.
The potential deal is being closely watched as investors assess whether financial markets remain willing to fund the rapid expansion of AI infrastructure.
Broadcom is seeking to expand its sales of chips and other data-centre equipment as AI companies such as Anthropic require increasing computing capacity.
Banks involved in the deal are expected to send syndication letters for the $42 billion Class A senior-secured tranche, according to Bloomberg's sources.
Blackstone is leading the $18 billion Class B junior debt tranche and has committed $9 billion from various funds, with plans to syndicate the remainder.
The potential financing could help companies including Anthropic gain access to chips and other infrastructure needed to expand their AI operations.
Reuters reported on Thursday that Anthropic's IPO filing showed Broadcom had agreed to lend the AI company up to $42 billion to finance infrastructure spending.
The proposed package adds to the hundreds of billions of dollars already raised to finance AI infrastructure.
While much of that funding has gone towards data centres, financing for chips and servers has also increased.
Nvidia announced a partnership with six major financial firms in August to mobilise more than $500 billion for AI infrastructure, including financing to help customers purchase its chips.
UBS maintains Buy rating on BroadcomBroadcom also received continued support from UBS, which reiterated its Buy rating and maintained a $470 price target following a virtual non-deal roadshow with Chief Executive Officer Hock Tan and Chief Financial Officer Kirsten Spears.
UBS analyst Timothy Arcuri said the firm saw a strong upward bias to Broadcom's fiscal 2027 and 2028 AI revenue guidance following discussions with management.
Broadcom's revenue increased 49% over the 12 months through the third quarter of fiscal 2026, while analysts are forecasting 66% revenue growth for fiscal 2026.
Arcuri also said investor concerns surrounding Broadcom's flagship TPU programme were misguided.
Broadcom said engagement remains strong for the next two generations of its XPU programme following the v8i ramp in 2027.
Broadcom said it is adding more SRAM and ARM CPU cores to its XPU devices for orchestration and management, increasing the complexity of the chips and making them more difficult for in-house design teams to replicate, according to UBS.
On financing for its initial frontier-lab customer, Broadcom said it "sells chips, not financial products" and is not providing direct financing. Instead, the company is contributing to a platform that allows the customer to access third-party lenders.
Broadcom is providing residual-value guarantees only for selected tranches, which management described as a small fraction of the overall financing.
UBS said the comments were consistent with previous discussions and maintained its estimates and $470 price target.
With a $470 target price, traders tracking the stock's momentum often turn to top online trading platforms to monitor price action around major financing and partnership news.
CJ CheilJedang (CJ, KRX: 097950), a global food and biotech company that owns a leading animal nutrition business (known as CJ Bio), and ADM (NYSE: ADM), a global leader in innovative solutions from nature, have agreed to form a new joint venture to secure a reliable, long-term source of feed-grade amino acids critical to the livestock industry, strengthening U.S. production, global supply chain resilience and U.S. food security.
“By combining CJ’s industry-leading fermentation technology to produce amino acids for animal nutrition and technical marketing with ADM’s U.S. manufacturing footprint and strong feedstock supply, the joint venture is positioned to seek enhanced cost competitiveness and support stable domestic production for North America,” said Lance Haeryong Choi, Senior Vice President of CJ CheilJedang. “Together, CJ and ADM will help to strengthen global food security and supply chain resilience as well as supporting American communities and manufacturing jobs.”
“Customers know that challenging global market conditions are putting continued U.S. domestic production of feed-grade amino acids, particularly lysine, at risk,” said Kris Lutt, ADM’s vice president of Innovation and Growth. “This joint venture will strengthen U.S. production, creating a more reliable U.S. source of supply by bringing together the right assets, products and capabilities to support continued production in a highly competitive environment. Recent decisions by the U.S. Department of Commerce and U.S. International Trade Commission to eliminate unfair trade practices affecting U.S. imports of lysine by China give us even greater confidence that this is the right step. ADM will continue to use its global fermentation capacity and expertise to meet customer needs and as a platform for growth as we explore new ways to serve food, feed and industrial markets through precision fermentation.”
The new joint venture will develop, manufacture and market fermentation-derived amino acids by bringing together:
CJ’s fermentation production facilities in Fort Dodge, Iowa, and Piracicaba, BrazilADM’s Decatur, Illinois, feed-grade amino acid plantCJ’s Mexico, Brazil and U.S. sales officesVia license, CJ’s intellectual property related to feed-grade amino acids for use by the joint venture within North and South AmericaCJ and ADM will give the JV exclusive rights to manufacture and sell feed-grade amino acids in the Americas.
CJ will be the majority owner of the joint venture.
CJ will retain ownership of its intellectual property and its global fermentation businesses outside the scope of the joint venture.
ADM’s other Decatur operations and its other global fermentation assets are not included in the transaction.
The launch date for the proposed joint venture is subject to customary closing activities as well as regulatory approvals.
About CJ CheilJedang
CJ CheilJedang is a South Korea-based food & biotech company operating globally. Founded in 1953 as the first Korean sugar manufacturer, it is now leading the global food industry with its renowned bibigo™ K-food products. It also operates an advanced green bio business known as CJ BIO, providing feed-grade amino acids under the BESTAMINO™ brand and food taste solutions made by its cutting-edge, fermentation-based bioengineering technologies. CJ CheilJedang is part of CJ Group, an international company in the fields of Food & Food Services, Bio & Pharma, Entertainment & Media, and Retail & Logistics. For more information, visit https://www.cj.co.kr/en.
About ADM
ADM unlocks the power of nature to enrich the quality of life. We’re an essential global agricultural supply chain manager and processor, providing food security by connecting local needs with global capabilities. We’re a premier human and animal nutrition provider, offering one of the industry’s broadest portfolios of ingredients and solutions from nature. We’re a trailblazer in health and well-being, with an industry-leading range of products for consumers looking for new ways to live healthier lives. We’re a cutting-edge innovator, guiding the way to a future of new bio-based consumer and industrial solutions. And we're leading in business-driven sustainability efforts that support a strong agricultural sector, resilient supply chains, and a vast and growing bioeconomy. Around the globe, our expertise and innovation are meeting critical needs from harvest to home. Learn more at www.adm.com.
Forward-Looking Statements Regarding ADM
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact they do not relate strictly to historical or current facts, and may include words such as "expect," "plan," "intend," "will," and other words and terms of similar meaning. Statements regarding the proposed joint venture and its business and operations, as well as the Company's business and actions, are subject to significant risks, uncertainties and changes in circumstances that could cause actual results and outcomes to differ materially from the forward-looking statements, including those described in Item 1A, "Risk Factors" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, as may be updated in subsequent Quarterly Reports on Form 10-Q.
Forward-Looking Statements Regarding CJ CheilJedang
This release may contain forward-looking statements regarding CJ’s business and the proposed joint venture. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ. CJ undertakes no obligation to update any forward-looking statements except as required by applicable law.
Source: ADM
Source: Corporate release
View source version on businesswire.com: https://www.businesswire.com/news/home/20261002828242/en/
QIAGEN získal od FDA povolení pro nový panel QIAstat-Dx BCID GN Plus AMR, který za zhruba hodinu odhalí 13 gramnegativních patogenů a 18 markerů rezistence.
Key Takeaways QGEN's new panel detects 13 gram-negative pathogens and 18 antimicrobial resistance markers.QIAGEN's two QIAstat-Dx panels cover 33 pathogen targets and 28 resistance markers in about one hour.QGEN also launched QIAmini, its third new sample preparation system introduced in 2026. QIAGEN N.V. (QGEN - Free Report) announced that U.S. laboratories now have access to its complete QIAstat-Dx bloodstream infection portfolio following FDA clearance of a new panel. The new QIAstat-Dx BCID GN Plus AMR Panel identifies gram-negative bacteria and antibiotic resistance markers in about one hour, complementing the recently FDA-cleared QIAstat-Dx panel for gram-positive bacteria and fungi.
The latest development expands the company’s QIAstat-Dx infectious disease testing menu in the United States, which already includes tests for respiratory and gastrointestinal infections, as well as meningitis and encephalitis.
Importance of QGEN’s New Bacteria Detection PanelBloodstream infections can progress rapidly and may lead to sepsis, a life-threatening response to infection that can result in organ failure and death. According to the U.S. Centers for Disease Control and Prevention, about 1.7 million adults in the United States develop sepsis each year, with at least 350,000 dying during hospitalization or being discharged to hospice. Faster identification of the cause of an infection can give clinicians important information to help guide treatment decisions.
The new Panel identifies 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers. More recently, QIAGEN earned FDA clearance for the QIAstat-Dx BCID GPF Plus AMR Panel, which detects 20 gram-positive bacterial and fungal pathogen targets as well as a broad pan-gram-negative target together with 10 genetic antimicrobial resistance markers from positive blood culture samples.
Together, the two panels cover 33 pathogen targets and 28 antimicrobial resistance markers. The gram-negative panel covers 13 pathogen targets and 18 resistance markers, while the gram-positive and fungal panel covers 20 pathogen targets and 10 resistance markers. Both deliver results in about one hour.
More Developments Within QIAGENThis month, QIAGEN announced the launch of QIAmini, a compact automated sample preparation system that offers research laboratories a time-saving and cost-efficient alternative to manual sample processing. It is the third new QIAGEN sample preparation system launched in 2026, following QIAsprint Connect for high-throughput research sample processing and QIAsymphony Connect for medium-throughput sample processing.
QGEN’s Industry ProspectsAccording to Fortune Business Insights, the bloodstream infection testing market was valued at $801 million in 2025 and is projected to witness a CAGR of 4.6% through 2034. The market is heavily influenced by rapid molecular diagnostics, automation in clinical microbiology, AI-assisted pathogen detection technologies, as well as the rising adoption of syndromic testing panels and real-time antimicrobial resistance monitoring systems.
Updates From QGEN PeersApart from QIAGEN, several key players in the bloodstream infection testing industry have recently made notable advancements.
Bruker (BRKR - Free Report) has introduced new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics and oligonucleotide analysis. The company made the announcement at the Human Proteome Organization World Congress 2026. This month, Bruker also received a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (“NMR”) instrumentation at the Pines Magnetic Resonance Center, which exceeds $6 million. The investment will enhance access to next-generation NMR technologies, including 800 MHz–class instrumentation.
Becton, Dickinson and Company (BDX - Free Report) , or BD, announced that Fairview Health Services has become the first health system in the United States to deploy the BD Vmax 160, a next-generation pharmacy automation robot. The system is designed to help manage the growing complexity of specialty therapies and refrigerated medicines in high-volume, centralized outpatient pharmacies. BD’s STANCE clinical trial evaluating GalaFLEX LITE Scaffold in breast revision surgery for capsular contracture reached its first enrollment milestone, with 274 patients treated across 33 active U.S. sites.
Thermo Fisher Scientific (TMO - Free Report) recently launched the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to support strong cell growth and protein production across CHO-K1 cell lines and is available in liquid and dry powder media formats. The company also introduced the Multiskan Ease Absorbance Microplate Reader to support protein quantification, enzyme-linked immunosorbent assays, cell viability studies, microbial growth monitoring and other routine laboratory applications with simplified operation and dependable performance. Thermo Fisher also announced the EMPAD G2 detector, designed to help researchers analyze materials in greater detail.
Cameco může těžit z rámce mezi USA a Jižní Koreou, který počítá až s osmi velkými jadernými reaktory v USA, včetně šesti Westinghouse AP1000 a až dvou korejských APR1400 na technologii Westinghouse. DOE navíc může podpořit až 10 dalších AP1000 a urychlit výstavbu až o tři roky.
Key Takeaways Cameco could benefit from plans for up to eight U.S. reactors, including six Westinghouse AP1000 units.The APR1400 plan could generate about $2 billion of Westinghouse value per reactor through various services.DOE financing could support up to 10 AP1000 reactors and may accelerate construction timelines by three years. Cameco Corporation (CCJ - Free Report) could see increased opportunities through its stake in Westinghouse following a new framework between the United States and South Korea aimed at expanding nuclear power capacity in the United States. The framework anticipates up to $120 billion of investment by South Korea to support the construction of as many as eight large nuclear reactors in the United States.
This includes six Westinghouse AP1000 reactors and up to two Korean APR1400 reactors based on Westinghouse technology. The framework is non-binding and remains subject to definitive agreements, site identification and planning, regulatory approvals, financing arrangements and other customary conditions.
The development is significant to Cameco because of its 49% ownership interest in Westinghouse Electric Company, with Brookfield Asset Management (BAM - Free Report) owning the remaining 51%. Westinghouse Electric Company is a nuclear reactor technology original equipment manufacturer (OEM) and a leading provider of highly technical aftermarket products and services to commercial nuclear power utilities and government agencies globally.
In November 2023, Cameco acquired a stake in Westinghouse through a strategic partnership with Brookfield Asset Management and its listed affiliate Brookfield Renewable Partners (BEP - Free Report) . It created a strategic platform combining Cameco's nuclear fuel expertise with Brookfield's experience in clean-energy and power-generation investments. With this move, Cameco positioned itself to benefit from both uranium demand growth and reactor construction activity. The company also owns a 49% interest in Global Laser Enrichment, providing additional exposure to uranium enrichment.
The latest framework builds on the strategic partnership announced in October 2025 between Cameco, Brookfield and the U.S. Department of Commerce to accelerate the deployment of Westinghouse nuclear technology in the United States. The framework contemplates a waiver under the 2025 settlement agreement reached by Westinghouse in its intellectual property dispute with Korea Electric Power Corporation and Korea Hydro & Nuclear Power Co., Ltd.
The one-time waiver would permit the construction of up to two APR1400 reactors in the United States, generating enhanced value for Westinghouse. The associated compensation package is expected to recognize the use of Westinghouse intellectual property and technology, providing approximately $2 billion of value per APR1400 reactor through a combination of intellectual property licensing, engineering and procurement services, subcontracting opportunities and the long-term supply of fuel fabrication services.
The company noted that the current framework is separate from the U.S. Department of Energy's (DOE) American Nuclear Supply Chain Loans conditional commitment announced in June 2026. Under that program, the DOE conditionally committed up to $17.5 billion to support the procurement of long-lead items for as many as 10 AP1000 reactors in the United States. Cameco expects the financing could accelerate AP1000 construction timelines by as much as three years.
These developments underscore the potential for government-backed financing and international cooperation to support a larger U.S. nuclear buildout, although both initiatives remain subject to significant execution and regulatory conditions. The broader nuclear expansion is being driven by rising demand for reliable electricity, including from data centers and Artificial Intelligence infrastructure. Against this backdrop, Constellation Energy Corporation (CEG - Free Report) , with its sizable U.S. nuclear generation portfolio, is well-positioned within the broader expansion of the U.S. nuclear ecosystem.
Seagate a Western Digital v pátek oslabily po zprávě, že Toshiba chce ve fiskálním roce 2027 zdvojnásobit kapacitu výroby HDD pro datová centra. Akcie Seagate klesly o 10 %, Western Digital o 7 % v premarketu.
Seagate Technology (STX) stock and shares of hard-disk drive rival Western Digital (WDC) slid early Friday, following a report that Toshiba is ramping up production of its drives.
Japan-based Toshiba plans to double production capacity for hard-disk drives used in data centers during its fiscal 2027, Nikkei reported. The news has clearly prompted concern among investors in Seagate and Western Digital, which dominate the market for hard-disk drives, or HDDs.
↑
X
AI Cyber Threat Sparks Stock Boom. One Analyst Reveals The Must-Own Plays.
Rising AI threats are fueling a surge in cybersecurity spending. Evercore ISI analyst Peter Levine analyzes whether the rally has room to run, naming top picks like CrowdStrike and Palo Alto Networks.
0 seconds of 16 minutes, 23 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
Cheap Chinese Models Threaten U.S. AI Dominance. So Why Is Nvidia's CEO Defending Them?
16:08
00:00
16:23
16:23
NOW PLAYING
AI Cyber Threat Sparks Stock Boom. One Analyst Reveals The Must-Own Plays.
On the stock market today, Seagate stock was down 10% at 847.86 in premarket trades. Western Digital stock dropped 7% to below 430.
Toshiba is a distant third in the global HDD market. But analysts have previously warned that the Japanese tech conglomerate could ramp up production in response to soaring data storage demand from AI. Hard-disk drives store about 80% of data within most cloud data centers, according to Western Digital's estimates.
The huge data center buildout has prompted a major rally for shares of Seagate and Western Digital, which recently rebranded as WD. Both companies have reported supply shortages that they are racing to meet by offering denser drives that hold more data.
Western Digital stock is ahead 168% year-to-date through Thursday, while Seagate is up 248%. Both companies have seen their rallies ease in recent weeks after a blistering first half of the year, however.
Seagate stock closed Thursday trading within a 14-week consolidation, according to IBD MarketSurge. However, shares appear set to break below their 50-day moving average once Friday's session begins.
Western Digital is 42% below its high from June and already trading below its 50-day.
YOU MAY ALSO LIKE:
Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The Buzz
These AI Stocks Took Off Or Tumbled In Q3. Here's Why.
Top Growth Stocks To Buy And Watch
Learn How To Time The Market With IBD's ETF Market Strategy
DuPont spustil digitální nástroj Sugar Separation Advisor, který pomáhá výrobcům cukru a sladidel vyhodnocovat chromatografické separace a navrhuje vhodné pryskyřice AmberLite k testování.
Key Takeaways DuPont launched a digital tool to help sugar and sweetener makers evaluate chromatographic separation options.The Sugar Separation Advisor predicts chromatograms and suggests AmberLite resins for further testing.DuPont raised its 2026 guidance after Q2 outperformance, citing stronger EBITDA and adjusted earnings. DuPont de Nemours, Inc.(DD - Free Report) is strengthening its position in the specialty chemicals market with the launch of the DuPont Sugar Separation Advisor, an interactive digital tool designed to help sugar and sweetener manufacturers evaluate chromatographic separation opportunities and identify suitable DuPont AmberLite resins for further testing.
DuPont, which is among the prominent players in the chemical space alongside Dow Inc. (DOW - Free Report) , Eastman Chemical Company (EMN - Free Report) and Celanese Corporation (CE - Free Report) , is focusing on innovation, productivity and growth across healthcare, water and industrial markets. The company's latest digital initiative expands access to its chromatography expertise and experimental separation data, while its broader portfolio includes solutions for healthcare, industrial water, food and beverage and other industrial applications.
The DuPont Sugar Separation Advisor builds on decades of chromatography application expertise and years of experimental separation data. The tool enables users to select a target sugar or sweetener, add up to four additional sugars or impurities to represent their feed stream and generate a predicted chromatogram based on experimental separation data. It then provides a qualitative separation assessment and suggests candidate DuPont AmberLite chromatography resins for further evaluation.
According to DuPont, the platform is designed to simplify the early stages of separation evaluation by helping customers identify promising resin options and focus laboratory testing. This could support manufacturers evaluating applications ranging from high-fructose corn syrup and beet sugar processing to rare sugars, oligosaccharides, polysaccharides and sugar alcohols.
DuPont developed the tool in response to recurring customer questions involving sugars and sweeteners such as allulose, tagatose, sorbitol, oligosaccharides, xylose and inositol. The resource displays laboratory-generated separation data for relevant sugar and resin combinations, helping users assess resin performance in application-relevant scenarios.
DuPont, in August, raised the midpoint of its full-year 2026 operating EBITDA and adjusted earnings guidance following its second-quarter outperformance. The company now expects net sales of $7.16-$7.19 billion, operating EBITDA of $1.75-$1.77 billion and adjusted earnings of $7.17-$7.32 per share. For the second half of 2026, DD projects net sales of $3.66-$3.69 billion, operating EBITDA of $890-$910 million and adjusted earnings of $3.65-$3.80 per share.
Dow expects approximately $200 million in additional benefits from its Transform to Outperform program in 2026, taking total in-year benefits from self-help initiatives to more than $1.3 billion. In the second half, the company plans to focus on growth and innovation in attractive end markets, portfolio investments and balanced capital allocation. DOW expects productivity and growth benefits from the program to accelerate through the remainder of 2026 and into 2027.
EastmanChemical expects 2026 earnings to improve significantly from 2025. Operating cash flow is projected to approach $900 million. For the third quarter, adjusted earnings are expected to be near the second-quarter level of $1.97 per share. Advanced Materials is expected to benefit from improved price-cost dynamics and asset utilization, while Fibers should gain from higher acetate tow purchases.
Celanese expects third-quarter adjusted earnings of $1.35-$1.75 per share and continues to project 2026 adjusted earnings of approximately $6 per share. The company maintained its full-year free cash flow guidance of $700-$800 million. Growth initiatives, productivity measures and portfolio and footprint actions are expected to support 2026 performance and strengthen cash generation.
Uvolnění pravidel pro spotřebu paliva má automobilkám do roku 2031 ušetřit asi 60,6 mld. USD na nákladech na dodržování předpisů. GM z toho má získat nejvíc, zhruba 20,4 mld. USD.
Key Takeaways GM could save $20.4B as revised fuel economy rules cut projected compliance technology costs.Automakers could save about $60.6B in compliance spending under the revised standards through 2031.NHTSA estimates 2031 vehicle costs could fall by $1,289 if automakers pass savings to buyers. The Trump administration has rolled back the fuel economy standards adopted under the Biden administration in 2024. The new rules cover passenger cars and light-duty trucks for model years through 2031 and are expected to take effect in December. The change will cut automakers' compliance-related technology spending by about $60.6 billion over the period, per the U.S. Department of Transportation as cited in Reuters.
A Lighter Fuel Economy Target for AutomakersThe 2024 Corporate Average Fuel Economy (CAFE) standards were designed to cut greenhouse gas emissions, reduce reliance on fossil fuels and push the market toward hybrids and electric vehicles. To meet them, automakers would have had to add more fuel-saving technology or sell more EVs.
The revised rules ease that pressure. The earlier standards projected a fleet-wide average of roughly 50.4 miles per gallon by model year 2031. Under the revised rules, the administration projects 34.9 mpg, a gap of more than 15 mpg.
GM Takes the Lead in Projected SavingsGeneral Motors (GM - Free Report) is set to gain the most from the rollback of federal fuel economy standards. Under the old rules, its technology costs through 2031 were estimated at $31.7 billion. The Transportation Department now expects the rollback to trim $20.4 billion from that figure, according to Reuters.
Other automakers also benefit, though by smaller amounts. Stellantis (STLA - Free Report) is expected to see its costs fall by $6.6 billion, followed by Ford (F - Free Report) at $5.8 billion. Toyota's (TM - Free Report) projected reduction is $4.5 billion, while Honda's (HMC - Free Report) is $4.1 billion.
These are projected cuts in compliance spending, not added profit. The uneven split suggests General Motors faced a steeper climb under the old standards than its Japanese rivals did.
The Affordability ArgumentU.S. Transportation Secretary Sean Duffy expects that lower compliance costs will help manufacturers expand U.S. production and make new vehicles more affordable. The National Highway Traffic Safety Administration (NHTSA) estimates that average per-vehicle costs for model year 2031 could fall by $1,289, but only if automakers pass the savings on to consumers.
Part of a Bigger ShiftThe rollback is the latest in a series of moves that have weakened the policy push toward cleaner vehicles under Trump. The July 2025 budget law ended the $7,500 federal EV tax credit, and that same month the administration dropped penalties for automakers who missed fuel economy targets. In February 2026, the EPA went further by repealing its vehicle greenhouse gas emissions standards. Environmental groups say the latest step reflects a broader retreat from climate and pollution priorities, noting that EVs produce fewer emissions than gasoline-powered cars.
What to Watch NextRelaxed rules do not necessarily mean buyers will stop caring about fuel costs. Drivers who want lower spending at the pump may keep favoring brands with strong fuel economy, particularly hybrid-heavy lineups. That could limit how far the rollback changes what people actually buy.
For investors and industry watchers, the key questions are whether automakers further slow their electrification plans, whether the savings show up in prices or in margins, and how the rules fare once they take effect in December.
Paramount Skydance CEO David Ellison announced Friday that upon closing his company's merger with Warner Bros. Discovery next week, the combined entity will be named Skydance.
It's a full-circle moment for a company that has undergone two major acquisitions within the last 18 months.
"Paramount and Warner Bros. shaped over a century of culture," Ellison wrote in social media post Friday. "By combining them, we aren't rewriting history — we're equipping these iconic studios with a more powerful engine. Together, we are Skydance: a creative-first home for bold, quality storytelling."
Ellison noted the new name allows the company to preserve Paramount and Warner Bros. as distinct studios. The merged company will trade under the new ticker "SKYD."
"We never wanted a new corporate identity to diminish, alter or overshadow either one," he said. "Instead, we wanted a name that would give the combined company an identity of its own while allowing Paramount and Warner Bros. — and all our extraordinary brands — to remain in the spotlight."
The Paramount and Warner Bros. studios together are set to release 35 films next year, according to data from Rentrak.
In August 2025, Ellison's Skydance — the production company behind "Mission Impossible" movies and "Top Gun: Maverick" — closed its acquisition of Paramount. Weeks later, the CEO set his sights on Warner Bros. Discovery in a takeover effort that would ultimately launch a bidding war.
In February, Paramount Skydance and Warner Bros. Discovery struck an agreement worth roughly $110 billion on an enterprise basis.
After settling a legal challenge brought by a group of state attorneys general, Paramount Skydance said this week the deal is expected to close on Tuesday.
Upon closing, Ellison and outgoing Mattel CEO Ynon Kreiz will serve as co-CEOs.
Rivian oznámil rekordní dodávky 19 248 vozů za 3. čtvrtletí a překonal odhad 18 001. Firma potvrdila výhled dodávek na rok 2026 na 65 000 až 70 000 vozů.
Rivian Automotive (RIVN.O) reported record third-quarter deliveries on Friday, beating analysts' estimates after rolling out its cheaper R2 SUV targeted at a broader section of the mass EV market.
Shares of the Irvine, California-based EV maker were up about 1.4% in premarket trading.
The R2, for which deliveries began in June, is seen by analysts as critical to Rivian's growth strategy, as the electric vehicle sector navigates a challenging US policy environment marked by the end of federal EV tax credits, tariffs and weaker industry-wide demand.
Before the R2, the EV maker's consumer lineup featured the R1S SUV and R1T pickup truck, both positioned as premium models.
Rivian delivered a record 19,248 vehicles in the quarter ended September 30, beating analysts' average estimate of 18,001 vehicles, according to data compiled by Visible Alpha.
The company also reaffirmed its 2026 delivery forecast of 65,000 to 70,000 vehicles, saying quarterly production and deliveries were in line with its expectations. Analysts on average estimate the EV maker will deliver 66,685 vehicles in 2026.
Rivian produced 19,751 vehicles at its manufacturing facility in Normal, Illinois, during the quarter.
The EV maker raised its annual delivery forecast in July, citing stronger-than-expected demand for the model.
It also struck a long-term partnership with Uber in March, under which the ride-hailing firm agreed to invest up to $1.25 billion in the EV maker and begin deploying fully autonomous R2 SUVs as robotaxis from 2028.
Rivian is scheduled to report third-quarter financial results on October 29.
Rivian svolává SUV R2 kvůli nedotaženým upevňovacím prvkům vysokonapěťové baterie, které mohou způsobit ztrátu výkonu za jízdy. Dotčeno může být asi 14 vozů.
Rivian has issued a recall for its R2 SUV after the company discovered that fasteners on its high-voltage battery pack might not be properly tightened, which can cause a loss of power while driving.
The company says only around 14 vehicles may have been affected, and that it will repair or replace damaged components on customer vehicles as needed.
This is the second recall Rivian has issued for the R2, which started shipping to customers this year. It’s an all-important vehicle for the company, as it’s the first Rivian EV meant for a mass market and is supposed to help it reach profitability for the first time. The first R2 recall, issued last month, had to do with the visibility of the backup camera and was addressed with a software update.
In a filing, the National Highway Traffic Safety Administration (NHTSA) said Rivian first spotted the defect on September 17. A “manufacturing operator” at the company’s Normal, Illinois factory noticed one of the fasteners had been “under torqued” by an “automated station” on the assembly line. The company investigated and reprogrammed the station to reject “improperly torqued fasteners.”
Rivian told the safety regulator that it “is not aware of any customer reports, accidents, injuries, or fatalities
related to this issue.” Some Reddit users, along with RivianTrackr, a blog that follows the company closely, reported about the issue late last month. One owner said Rivian’s service department told them to stop driving immediately, and the company towed the vehicle.
Rivian has set an aggressive goal for the launch of the R2. The company has said it plans to ship between 20,000 and 25,000 of them by the end of this year. With deliveries starting in June, that would make it one of the fastest launches of a new EV in the U.S. market if Rivian pulls it off. The company is supposed to be adding a second production shift to hit those numbers, and has said early demand is strong for the new, more affordable SUV.
Topics
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.
Sean O’Kane is a reporter who has spent a decade covering the rapidly-evolving business and technology of the transportation industry, including Tesla and the many startups chasing Elon Musk. Most recently, he was a reporter at Bloomberg News where he helped break stories about some of the most notorious EV SPAC flops. He previously worked at The Verge, where he also covered consumer technology, hosted many short- and long-form videos, performed product and editorial photography, and once nearly passed out in a Red Bull Air Race plane.
You can contact or verify outreach from Sean by emailing [email protected] or via encrypted message at okane.01 on Signal.
Key Takeaways Rivian plans to equip employee R2 vehicles with LiDAR and RAP1 by year-end 2026.Customer deliveries of the new autonomy hardware are expected to begin in 2027.Rivian aims to expand the technology across its full Autonomy fleet later next year. Rivian Automotive, Inc. (RIVN - Free Report) plans to equip its first R2 vehicles with LiDAR and an internally developed RAP1 autonomy computer for employees by the end of 2026, while customer deliveries are expected to begin in 2027, per Electrek. This timeline could be viewed as a shift from the company’s earlier communications.
Rivian introduced its third-generation autonomy hardware, the RAP1 chip, last December. The system is rated at 1,600 sparse INT8 TOPS and is designed to work with LiDAR on the R2. At the time, Rivian said the technology would arrive in late 2026. However, the R2 launched in June without the new hardware. A production-ready-looking R2 equipped with LiDAR was later spotted near Rivian’s Irvine headquarters.
Per Rivian’s VP of Investor Relations Chip Newcom, production of the RAP1 system will initially be focused on the R2, with employees receiving the technology first. The company plans to install the third-generation computer and LiDAR in employee vehicles later this year before expanding the rollout to customers in 2027. Thus, Rivian’s late 2026 target remains technically intact, although it initially applies only to employees. The company has not specified when customer deliveries will begin in 2027. Per Rivian, the LiDAR and dual-RAP1 hardware are now included in automotive cost of goods and have become relatively inexpensive.
According to Rivian’s SVP of Autonomy & AI James Philbin, the rollout is expected to begin toward year-end, initially reaching early-adopter customers with R1 Gen 2 vehicles and later Gen 2 hardware revisions. This includes fleets Rivian classifies as Phase II and Phase III. The company aims to extend the technology across its full Autonomy+ fleet later next year, although certain use cases, such as parking lots, may not be supported in the initial version.
Latest Updates on Autonomous Mobility by Other AutomakersLucid Group, Inc. (LCID - Free Report) and Bolt, a leading European shared mobility platform, have entered into a strategic partnership to develop and launch autonomous mobility services across Europe. The collaboration will combine Lucid’s software-defined vehicle platform with Bolt’s European mobility data, operational infrastructure and industry expertise. As part of the partnership, Lucid and Bolt will jointly develop an autonomous driving system-ready vehicle platform designed to support SAE Level 4 autonomous mobility from the product-development stage.
Tesla, Inc. (TSLA - Free Report) is also advancing its autonomous-driving efforts in Europe. France has begun testing two vehicles to further evaluate Tesla’s Full Self-Driving (“FSD”) advanced driver-assistance system. In April, the Netherlands’ road authority RDW provisionally approved Tesla’s FSD system for use on Dutch roads, prompting Belgium, Denmark, Estonia and Lithuania to take similar steps ahead of a potential bloc-wide vote on the system.
Published in auto-tires-trucks autonomous-vehicles electric-vehicles
Tesla and Rivian both released their third-quarter delivery numbers this week, and the market is treating the two reports as if they came from different planets. Here is why one stock is surging while the other quietly sinks.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Two electric vehicle makers released third-quarter 2026 delivery reports, and the market is sending Tesla (NASDAQ:TSLA | TSLA Price Prediction) and Rivian Automotive (NASDAQ:RIVN) in opposite directions. Tesla stock is up 5% to $372.64 after the company exceeded a delivery consensus it compiled and published itself. Meanwhile, Rivian stock is slipping 3% to $14.28, even though the company called its quarter in line with management’s outlook.
For sector context, the Global X Autonomous & Electric Vehicles ETF (NASDAQ:DRIV) is up 2% to $33.73, a much smaller advance than the one in Tesla stock. Meanwhile, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is also up less than 1.1% to $772.43, a solid but comparatively modest gain for the broad market. That gap places the strength in Tesla stock specifically, while electric vehicle makers as a group are moving up far less.
Tesla Tops Its Own Delivery Consensus Tesla reported delivering 486,532 vehicles in the third quarter, the headline number behind the rally. The consensus estimate Tesla compiled internally and released earlier in the week stood at 461,974 vehicles. Clearing a figure the company assembled itself carries weight, since that internal consensus is the bar this particular release is usually measured against.
One problem sits in Tesla’s year-ago comparison, which limits how much the beat says about demand. In the same quarter a year earlier, Tesla delivered 497,099 vehicles. The figures show Tesla clearing expectations. Its deliveries still trailed the prior-year total, so Tesla’s growth question stays open even after a clean beat.
Rivian Slips as the Sector Fund Lags Tesla Separately, Rivian reported its own third-quarter production and delivery totals, and the company stated that those results were in line with its outlook. An in-line report removes one source of uncertainty for Rivian, though it offers none of the upside surprise that Tesla posted, and Rivian stock is still lower, which shows how little credit an in-line quarter is earning when a larger rival posts a beat.
The Global X DRIV fund spreads its assets across automakers, chipmakers, battery suppliers and autonomous driving companies, with Tesla among its holdings. That breadth helps explain why the fund is rising far less than Tesla stock, because one name’s gain gets diluted across many other positions, and a rally concentrated in Tesla stock produces exactly that pattern, with the sector fund edging higher as Tesla shares surge.
A range of other electric vehicle makers sit inside the same Global X DRIV ETF, giving the basket exposure well beyond Tesla.
What to Watch Next Tesla will report later this month. It will release its full third-quarter financial results after trading ends for the day, with a management question-and-answer webcast to follow. Shareholders can stay tuned for that report, which may show whether the delivery beat carries through to Tesla’s revenue and margins. Any sign that the beat lifted Tesla’s profitability could matter as much as the delivery count itself.
Tesla’s quarter exceeded the company’s own consensus but trailed the prior-year total, leaving both the bull case and the bear case intact. Investors considering their exposure should size their positions with care, as Tesla’s growth question stays open and Rivian stock is lower even after an in-line quarter. Keeping one’s position sizes moderate leaves room to respond once Tesla reports its full financial results.
Contact [email protected] for any questions or corrections.
Cycurion oznámila, že znovu splnila požadavek Nasdaq na minimální nabídkovou cenu 1,00 USD za akcii. Po reverzním splitu 1:8 držela nabídková cena nad 1,00 USD deset po sobě jdoucích obchodních dnů.
MCLEAN, Va., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leading AI-driven, tech-enabled cybersecurity solutions provider, today announced that it has received a letter, dated October 1, 2026, from the Hearings Office of The Nasdaq Stock Market LLC confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(1), the minimum bid price requirement of $1.00 per share, as required by the Nasdaq Hearings Panel’s decision letter dated September 9, 2026.
The October 1 letter confirms that the Company has regained compliance with Listing Rule 5550(a)(1). Nasdaq staff’s compliance worksheet, referenced in the letter, states that on August 28, 2026 the Company effected a 1-for-8 reverse stock split and that, since then, the Company’s bid price has closed above $1.00 for 10 consecutive trading days. The Company’s common stock continues to trade on the Nasdaq Capital Market under the symbol CYCU.
The September 9, 2026 Panel decision granted the Company’s request for continued listing subject to demonstrating bid-price compliance on or before September 11, 2026. The October 1 letter confirms that condition has been met.
In application of Listing Rule 5815(d)(4)(A), the Company will be subject to a Discretionary Panel Monitor for one year from October 1, 2026, through October 1, 2027. If the Company fails to maintain compliance with any continued listing requirement during that period, Nasdaq staff will issue a delist determination letter, and the Company will not be permitted to submit a plan of compliance or receive additional time from staff to regain compliance. The Company may request a hearing, which the Nasdaq Hearings Department would promptly schedule. The Hearings Panel will consider the Company’s compliance history in any such decision.
“Nasdaq’s letter confirms that we met the bid-price condition in the Panel’s decision,” said Kevin Kelly, Chairman and Chief Executive Officer of Cycurion. “The common stock continues to trade on Nasdaq. We understand the monitor, and meeting Nasdaq’s listing standards has been, and remains, a priority for the Company.”
About Cycurion, Inc.
Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of IT cybersecurity and AI solutions, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies LLC, Cloudburst Security LLC, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients committed to securing the digital future. More info: www.cycurion.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Such statements include, but are not limited to, the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements, including during the Discretionary Panel Monitor period through October 1, 2027; the continued listing and trading of the Company’s common stock on the Nasdaq Capital Market; the operations and prospective growth of the Company’s business; and other statements that are not historical facts, including statements which may be accompanied by words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Cycurion and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to, the Company’s ability to maintain a closing bid price of at least $1.00 per share and to satisfy Nasdaq’s other continued listing requirements; the fact that, during the Discretionary Panel Monitor period, any failure to maintain compliance will result in a delist determination without the opportunity to submit a plan of compliance or obtain additional time from Nasdaq staff; the outcome of any hearing that may follow such a determination; the effect of the reverse stock split on the market price, trading volume, and liquidity of the Company’s common stock; volatility in the Company’s stock price; any potential legal proceedings; and the future performance of the Company’s stock. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K filed by Cycurion with the U.S. Securities and Exchange Commission. Cycurion anticipates that subsequent events and developments may cause its plans, intentions, and expectations to change. Cycurion assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Cycurion’s plans and expectations as of any subsequent date.
CRISPR Therapeutics oznámila, že na ACR Convergence 2026 představí data z fáze 1 pro zugo-cel u autoimunitních onemocnění. Poster se zaměří na bezpečnost a účinnost u refrakterní systémové sklerózy.
ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.
Title: Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy Zugocabtagene Geleucel (zugo-cel) in Patients with Refractory Systemic Sclerosis
Session Type: Poster Presentation
Abstract Number: 0225
Session Name: Poster Session A
Date and Time: Sunday, November 8, 2026, 10:30 a.m. ET
Zugo-cel is being evaluated in Phase 1 trials across autoimmune diseases, including rheumatologic, hematologic and neurologic indications.
A copy of the presentation will be available at www.crisprtx.com once the presentation concludes.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
CRISPR THERAPEUTICS® standard character mark and design logo and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners.
CRISPR Therapeutics Forward-Looking Statement
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding any or all of the following: (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials and expectations regarding data, safety and efficacy generally; (ii) data included in the above-described poster presentation and any associated abstract; and (iii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9, as well as other technologies. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in CRISPR Therapeutics most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.
Wolfspeed uvedl na trh prémiový 200mm n-type silicon carbide substrát a rozšířil portfolio 200mm SiC. Akcie v reakci na širší rally polovodičů po výsledcích Micronu 1. října vzrostly o více než 10 %.
Wolfspeed Inc. (NYSE:WOLF) had a busy week that included an expansion of its 200mm silicon carbide portfolio and a broader semiconductor rally fueled by Micron’s strong earnings.
Wolfspeed stock is trading at elevated levels. What’s next for WOLF stock? New Premium Substrate LaunchOn September 27, Wolfspeed announced the commercial availability of its new Premium 200mm n-type silicon carbide substrate, expanding its 200mm SiC materials portfolio with a higher-quality starting material designed to improve yield through reduced defects and greater wafer-shape stability. The product delivers fewer than 0.01 micropipes per square centimeter, or fewer than three micropipes per wafer, as validated by X-ray topography, alongside low threading screw dislocations and improved wafer-shape and lot-to-lot consistency.
“Wolfspeed leads in advancing silicon carbide materials technology, and this latest addition to our 200 mm portfolio reflects our expertise behind those efforts,” said Dr. Cengiz Balkas, EVP of the Materials Business Unit at Wolfspeed. “We’re giving customers a stronger foundation for developing increasingly demanding silicon carbide devices, backed by the manufacturing experience and scale to support them as needs grow.”
Micron’s Earnings Lift Semiconductor StocksSeparately, Micron reported fiscal fourth-quarter results on September 30 that beat expectations on both the top and bottom lines, with adjusted earnings per share of $33.42 against a consensus estimate of $45, and revenue of $54.22 billion against an estimate of $50.75 billion. The strong report reinforced confidence that AI infrastructure demand remains intact, lifting semiconductor stocks broadly, including Wolfspeed, which rose more than 10% on October 1.
Read Next
Wolfspeed Shares Edge HigherWOLF Price Action: At the time of publication, Wolfspeed shares are trading 3.63% higher at $32.30, according to data from Benzinga Pro.
Image via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
Aqua Pennsylvania koupila vodárenská aktiva Ulster Municipal Authority za 0,5 mil. USD a přidá 180 zákazníků. V příštích pěti letech plánuje investovat 2 mil. USD do modernizace sítě.
Key Takeaways WTRG's Aqua Pennsylvania bought Ulster's water system assets for $0.5M, adding 180 customers.Aqua Pennsylvania plans $2M of upgrades over five years to modernize facilities and replace aging lines.Essential Utilities has signed deals covering over 200,000 customers and an active 400,000-customer pipeli Essential Utilities, Inc. (WTRG - Free Report) announced that its subsidiary, Aqua Pennsylvania, acquired the water system assets of the Ulster Municipal Authority in Bradford County for $0.5 million. This new acquisition will increase the existing water customer base by 180 customers.
Aqua Pennsylvania plans to invest $2 million in upgrades to the acquired water system assets of the Ulster Municipal Authority in Bradford County over the next five years and provide quality services to the customers in the region.
These infrastructure upgrades aim to modernize facilities, replace aging lines and provide safe, high-quality water for all residents of Ulster.
Fragmented Water Utilities Offer Acquisition OpportunitiesEssential Utilities is quite active in expanding its operations through acquisition. Since 2015, the company has added more than 138,000 customers or equivalent dwelling units and about $570 million of rate base through acquisitions. In May 2026, Essential Utilities acquired Integra Water Texas for $4.9 million, adding about 1,100 wastewater customers after closing Greenville earlier in the year. Signed purchase agreements represent more than 200,000 customers and about $282 million in purchase price, while the active municipal acquisition pipeline is about 400,000 customers. Essential Utilities’ proposed American Water Works (AWK - Free Report) merger remains targeted for the first quarter of 2027.
American Water Works is expanding its customer base through regulated acquisitions as well as organic growth. Through June 30, 2026, the company added about 52,000 customer connections from acquisitions, including roughly 47,000 connections from the Nexus systems acquired on June 1. The Nexus transaction expanded operations across eight states and was completed ahead of the company’s initial timeline.
Another water utility, California Water Service Group (CWT - Free Report) , stated that it has agreed to acquire Nexus Water Group’s Nevada and Oregon water and wastewater systems for $218 million. The company completed the acquisition of Palm Mutual Water Company in July 2026, which added more than 300 customers.
Recently, Select Water Solutions (WTTR - Free Report) agreed to acquire Pilot Water Solutions for $700 million, plus up to $15 million in contingent consideration. Pilot Water Solutions adds extensive Delaware Basin infrastructure, long-term contracted revenues and significant disposal capacity. The combination will expand Select Solutions’ water midstream platform, pipeline network, recycling capacity and produced-water storage footprint
Avient spustila Nymax FR REC s 42–77 % postindustriálního recyklátu pro elektrické aplikace. Materiál nabízí nehalogenové složení bez PFAS a splňuje UL 94 V-0.
Key Takeaways Avient launches Nymax FR REC grades with 42-77% post-industrial recycled content for electrical uses.The materials offer UL 94 V-0 performance and non-halogenated, non-PFAS formulations for OEMs.New grades help OEMs and component manufacturers address fire-safety requirements alongside circularity goals. Avient Corporation (AVNT - Free Report) declared the launch of Nymax FR REC flame-retardant recycled polyamide grades, addressing the growing demand for more sustainable materials amid the company’s accelerating electrification and circularity initiatives. The new grades combine non-halogenated fire safety performance with 42-77% post-industrial recycled content, helping manufacturers achieve uncompromising fire safety along with aggressive sustainability targets.
Avient, which is among the prominent mid-cap chemical companies along with Innospec Inc. (IOSP - Free Report) , Quaker Chemical Corporation (KWR - Free Report) and Cabot Corporation (CBT - Free Report) , will showcase the Nymax FR REC portfolio at the upcoming Fakuma international trade fair in Germany. The launch will mainly target residential and institutional power distribution systems.
As increasing bans on per- and polyfluoroalkyl substances (PFAS) emerge, original equipment manufacturers (OEMs) are eager to lower the product’s carbon footprint. The system can be used widely across various applications, including switchgear, busway and connectors, appliances, BESS, and EV charging infrastructure.
The new materials deliver UL 94 V-0 performance at 0.8 millimeters and a 960°C glow-wire flammability index, supporting compliance with global electrical safety standards. The formulations also offer comparative tracking index values of up to 600 V and use non-halogenated, non-PFAS formulations, aligning with regulatory requirements.
The portfolio includes PA6 and PA66 resins with 15-40% glass-fiber loading, along with unfilled options. By incorporating recycled feedstock while maintaining flame-retardant performance, Avient aims to help OEMs and component manufacturers address fire-safety requirements alongside circularity goals.
Avient, in August, raised its full-year 2026 adjusted earnings guidance to $3.10-$3.25 per share from the previous range of $2.93-$3.17. The revised range implies adjusted earnings growth of 10-15% over 2025. Management cited year-to-date performance and visibility into third-quarter demand in raising its expectations. The company also increased its full-year adjusted EBITDA guidance to $575-$603 million. Avient expects to repay $100-$150 million of debt during 2026, including the $50 million repaid in the second quarter. Management remains focused on targeted investments in prioritized growth portfolios while pursuing continued earnings growth and balance-sheet improvement.
Another industry leader, Innospec, expects its Performance Chemicals segment to benefit from ongoing plant repairs, process improvements, upgrades and additional top-line and margin opportunities. For Oilfield Services, Innospec expects its DRA expansion and opportunities in completions and production to support further sequential gains. Fuel Specialties, meanwhile, is expected to continue advancing opportunities across its established and newer end markets. IOSP continues to pursue opportunities across traditional fuel, renewable fuel and non-fuel applications.
Quaker Chemical, on its second-quarter call, released its third-quarter guidance, reflecting expectations of stable demand, with end markets projected to remain flat to slightly positive through the rest of 2026. Continued share gains are expected to support volume growth despite macroeconomic and geopolitical uncertainty. KWR expects the gross margin percentage in the third quarter to remain near second-quarter levels as it works through raw material cost inflation, inventory movements and the timing of price recovery actions. Management said pricing and cost initiatives should allow the company to exit 2026 within its target gross margin range. The company continues to expect meaningful revenue and adjusted EBITDA growth in 2026.
Cabot, for fiscal 2026, tightened its adjusted earnings guidance to $6.15-$6.45 per share from the previous range of $6-$6.5. The company expects its full-year fiscal 2026 operating tax rate to be in the range of 28-30%. It also reaffirmed its expectation of approximately $40 million of EBITDA from its battery materials product line for fiscal 2026. CBT is expanding global conductive additive capacity through targeted investments in the United States and China to support expected growth in global battery demand and broaden its participation with leading battery manufacturers.
EMCOR ve 2. čtvrtletí zvýšil tržby o 19,8 % na rekordních 5,15 miliardy USD a EPS vzrostl o 34,8 % na 9,06 USD. RPO dosáhly rekordu 17,14 miliardy USD.
Key Takeaways EMCOR's Q2 revenues rose 19.8% to a record $5.15 billion, while EPS surged 34.8% to $9.06.EME's record $17.14 billion RPOs reflect strong demand across data centers and other key markets.Five electrical acquisitions add about $625 million in revenues and expand EMCOR's market capabilities. EMCOR Group, Inc. (EME - Free Report) is proving that being everywhere infrastructure dollars are flowing can be a powerful growth strategy. From AI data centers and high-tech manufacturing to water, healthcare and institutional projects, EMCOR’s broad end-market exposure is helping it capture multiple growth waves rather than rely on a single infrastructure cycle.
The momentum was evident in the second quarter of 2026, wherein revenues jumped 19.8% year over year to a record $5.15 billion, while operating income surged 31.8% to $547.3 million. Operating margin expanded 100 basis points to 10.6% and EPS (earnings per share) soared 34.8% to $9.06. Remaining Performance Obligations, or RPOs, reached a record $17.14 billion, up 43.9% year over year and 29% from December 2025. Network & Communications, Water & Wastewater, and Institutional and Healthcare were among the biggest contributors.
AI infrastructure remains a major engine. Customer spending on data centers and digital transformation is driving unprecedented activity in Network & Communications. But EMCOR’s growth story goes well beyond data centers. Water and wastewater, healthcare, institutional and manufacturing markets are also generating robust demand. EME is also using M&A to widen its reach. Five recently announced electrical acquisitions bring roughly $625 million in trailing-12-month revenues, $105 million in EBITDA and about 1,500 employees. The deals strengthen its presence across key markets while adding capabilities in data centers, manufacturing, healthcare and institutional projects.
Labor shortages, tariffs, supply-chain volatility and project-mix shifts remain risks. Still, EMCOR’s diversified demand base, technical expertise and acquisition strategy could make its broad market footprint a meaningful competitive advantage.
EMCOR, MasTec & Quanta: The Great Infrastructure Growth ShowdownEMCOR is positioned to benefit from sustained U.S. public infrastructure spending, alongside close market peers, including MasTec, Inc. (MTZ - Free Report) and Quanta Services, Inc. (PWR - Free Report) . But their exposure differs.
EME’s broad mix across electrical and mechanical construction, data centers, healthcare, water and wastewater, institutional and manufacturing markets provides multiple growth avenues. Meanwhile, MasTec’s $21.4 billion backlog reflects momentum across clean energy, power delivery, pipelines and communications, while Quanta’s broader utility and power infrastructure footprint targets grid modernization, transmission, generation and AI-driven electricity demand.
Quanta and MasTec offer deeper exposure to power infrastructure tied to AI, while EMCOR has a wider building-services and end-market mix. EME’s competitive edge is diversification, customer breadth and cross-trade capabilities, potentially reducing reliance on any single infrastructure cycle and supporting resilience across demand cycles.
Morgan Stanley 1. října 2026 zahájila pokrytí Lennar s ratingem Underweight a cílovou cenou 65 USD. Berkshire Hathaway mezitím navýšila podíl v Lennar na zhruba 26,6 milionu akcií.
Morgan Stanley just issued a sell rating on a homebuilder that Berkshire Hathaway keeps buying in larger and larger quantities, and the reasoning behind each side reveals a fundamental disagreement about time, risk, and when housing recovers.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
On October 1, 2026, Morgan Stanley (NYSE:MS | MS Price Prediction) started covering Lennar (NYSE:LEN) with an Underweight rating, its version of a sell rating. It set a $65 price target.
Lennar shares barely moved. The stock rose 0.67% in that session and closed at $82.14. It had already fallen 18.88% year to date, so investors had likely priced in much of the bad news.
The buyer on the other side helps explain the calm. Berkshire Hathaway (NYSE:BRK-B) crossed 10% ownership of Lennar, and it kept buying through the end of the month.
That puts a major bank’s bearish call against a long-term owner looking to buy more. Both can read the same numbers because they operate on different time frames.
Morgan Stanley’s Objection Is About Margin Morgan Stanley wrote that “Lennar’s land-light transition needs to deliver better earnings, and higher finished lot costs and sustained incentives could offset the benefit.”
Land-light means Lennar buys options on lots from outside property owners instead of owning the land itself. This ties up less capital but reduces profit. Lennar owns fewer than 2.5% of about 488,000 controlled lots.
Gross margin on home sales already fell to 15.8% in the fiscal third quarter, down from 17.5% a year earlier, and incentives ran near 12.0%.
Morgan Stanley also rated two other builders Underweight. Its only Overweight went to Toll Brothers (NYSE:TOL), with a $159 target.
This rating adds to an already bearish majority. Lennar has 5 strong sell and 3 sell ratings, compared with 1 buy, 1 strong buy, and 8 holds. The consensus target of $80.08 sits below the share price, meaning the average analyst sees downside, though targets often lag reality.
What Berkshire Is Buying Berkshire held 13.1 million shares at the end of June. The stake reached about 26.6 million shares after purchases from September 28 through September 30. The timeline complicates any link to Warren Buffett. Berkshire’s original 2023 stake was about 153,000 shares. Buffett stepped down as chairman on September 18, with Greg Abel as chief executive.
Berkshire does not disclose which manager makes each purchase, so whether this is a Buffett call or an Abel call remains an open question (if you want to borrow Buffett’s homework elsewhere, we sorted the seven cheapest dividend payers in Berkshire’s portfolio into a free report here).
At this price, a buyer gets a large controlled land position, homebuilding debt at only 16.6% of total capital, and a claim on the day homes become affordable again. Berkshire can wait a full cycle for that return. Morgan Stanley is estimating the next few quarters.
Weak Results and Rising Rates Pressure Lennar Adjusted EPS of $1.23 missed the $1.30 consensus. Management cut full-year delivery guidance to 80,000 to 81,000 homes.
The 10-year Treasury yield rose to 5.29% on September 30. Higher rates make mortgage buydowns more expensive, putting the fourth-quarter margin guide of 15.5% to 16.0% at risk.
Berkshire can wait years without harm. A retiree holding shares with a -34.68% one-year return may not have that patience.
Toll Brothers, Morgan Stanley’s preferred builder, sells to wealthier buyers who depend less on financing incentives. Berkshire shareholders hold Lennar as one small part of a diversified company.
Watch fiscal fourth-quarter gross margin. A result below 15.5% would support Morgan Stanley’s case. A close below the $75.70 52-week low would put the stock at a new 52-week low.
Contact [email protected] for any questions or corrections.
Cable One jedná v pokročilé fázi o financování s GTCR a dalšími věřiteli, aby posílila kapitálovou strukturu. Zatím ale nebyla uzavřena žádná definitivní dohoda.
PHOENIX--(BUSINESS WIRE)--Cable One, Inc. (NYSE: CABO) (“Cable One” or the “Company”) today announced it is in advanced discussions with GTCR LLC (“GTCR”), certain of its existing lenders and a consortium of leading private lending institutions regarding financing transactions to address certain of the Company’s forthcoming capital needs. Cable One is working towards enhancing its capital structure to position the company to drive growth in shareholder value.
“We are pleased at the momentum and interest from existing stakeholders and new investors, who are collaborating with us to formulate a solution that supports the future of Cable One. The contemplated financings are intended to strengthen Cable One’s overall financial position,” said Jim Holanda, Chief Executive Officer of Cable One.
“GTCR has been working closely with Cable One to facilitate a potential transaction that would bring new capital into the business and highlight its unrealized potential. Our close work together underscores our conviction in the business as an enduring leader in its industry,” said Stephen J. Jeschke, Managing Director at GTCR. “Throughout this process, our focus has been on developing a solution that supports a sustainable path forward for the business and we look forward to the opportunity to participate in Cable One’s next phase of growth in close partnership.”
While all parties are working diligently on the financing transactions, no definitive agreements have been entered into thus far, and there can be no guarantee that any transaction will materialize.
Separately, Cable One and GTCR have agreed to an extension of the deadline for the completion of Cable One’s purchase of the 55% remaining stake that Cable One does not already own in Mega Broadband Investments Holdings LLC to October 9, 2026.
About Cable One
Cable One, Inc. (NYSE:CABO) is a leading broadband communications provider delivering exceptional service and enabling approximately 1 million residential and business customers across 24 states to thrive and stay connected to what matters most. Through Sparklight®, the brand our customers know and trust, we’re not just shaping the future of connectivity – we’re transforming it with a commitment to innovation, reliability, and customer experience at our core.
Our robust infrastructure and cutting-edge technology don’t just keep our customers connected; they help drive progress in education, business, and everyday life. We’re dedicated to bridging the digital divide, empowering our communities, and fostering a more connected world. When our customers choose Cable One, they are choosing a team that is always working for them–one that believes in the relentless pursuit of reliability, because being a trusted neighbor isn’t just what we do – it’s who we are.
About GTCR
Founded in 1980, GTCR is a leading private equity firm that invests behind The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $35 billion in over 300 companies, and the firm currently manages $45 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.
Forward-Looking Statements
This communication may contain “forward-looking statements” that involve risks and uncertainties. These statements can be identified by the fact that they do not relate strictly to historical or current facts, but rather are based on current expectations, estimates, assumptions and projections about the Company’s industry, business, strategy, technologies, acquisitions and strategic investments, market expansion plans, dividend policy, capital allocation, financing strategy, the put option associated with the remaining equity interests in Mega Broadband Investments Holdings LLC (“MBI”), which was exercised on January 2, 2026 (the “Put Option”), the purchase price payable pursuant to the Put Option (such purchase price, the “Put Price”), the anticipated timeline to consummate such transaction, the Company’s ability and sources of capital to fund the Put Price, MBI’s future indebtedness and the Company’s financial results and financial condition. Forward-looking statements often include words such as “will,” “should,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” “plans,” “believes” and words and terms of similar substance in connection with discussions of future operating or financial performance. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company’s actual results may vary materially from those expressed or implied in its forward-looking statements. Accordingly, undue reliance should not be placed on any forward-looking statement made by the Company or on its behalf. Important factors that could cause the Company’s actual results to differ materially from those in its forward-looking statements include government regulation, economic, strategic, political and social conditions and the following factors, which are discussed in the Company’s latest Annual Report on Form 10-K and in its subsequent filings with the Securities and Exchange Commission (the “SEC”), including its latest Quarterly Report on Form 10-Q:
rising levels of competition from historical and new entrants in the Company’s markets; recent and future changes in technology, and the Company’s ability to develop, deploy and operate new technologies, service offerings and customer service platforms; risks associated with the Company’s use of artificial intelligence; the Company’s ability to grow its residential data and business data revenues and customer base; increases in programming costs and retransmission fees; the Company’s ability to obtain hardware, software and operational support from vendors, including the potential impacts of changes in trade policy and tariffs; risks relating to existing or future acquisitions and strategic investments by the Company, including risks associated with the exercise of the Put Option associated with the remaining equity interests in MBI and the acquisition and integration of MBI; the integrity and security of the Company’s network and information systems; the impact of possible security breaches and other disruptions, including cyber-attacks; the Company’s failure to obtain necessary intellectual and proprietary rights to operate its business and the risk of intellectual property claims and litigation against the Company; the Company’s ability to maintain effective internal control over financial reporting and disclosure controls and procedures; impairments of intangible assets and goodwill; legislative or regulatory efforts to impose new requirements on the Company’s data services; additional regulation of the Company’s video and voice services or changes to government subsidy programs; the Company’s ability to renew cable system franchises; increases in pole attachment costs; changes in local governmental franchising authority and broadcast carriage regulations; the potential adverse effect of the Company’s level of indebtedness on its business, financial condition or results of operations and cash flows; the restrictions the terms of the Company’s indebtedness place on its business and corporate actions; the possibility that interest rates will rise, causing the Company’s obligations to service its variable rate indebtedness to increase significantly; risks associated with the Company’s indebtedness, including the Company’s ability to pay dividends on, make distributions in respect of, repurchase or redeem, capital stock; provisions in the Company’s charter, by-laws and Delaware law that could discourage takeovers and limit the judicial forum for certain disputes; adverse economic conditions, labor shortages, supply chain disruptions, changes in rates of inflation and the level of move activity in the housing sector; pandemics, epidemics or disease outbreaks, such as the COVID-19 pandemic, have, and may in the future, disrupt the Company’s business and operations, which could materially affect the Company’s business, financial condition, results of operations and cash flows; lower demand for the Company’s residential data and business data products; fluctuations and/or declines in the Company’s stock price; dilution from equity awards, convertible indebtedness and potential future convertible debt and stock issuances; damage to the Company’s reputation or brand image; the Company’s ability to retain key employees (whom the Company refers to as associates); the Company’s ability to incur future indebtedness; provisions in the Company’s charter that could limit the liabilities for directors; and the other risks and uncertainties detailed from time to time in the Company’s filings with the SEC, including but not limited to those described under “Risk Factors” in its latest Annual Report on Form 10-K, its latest Quarterly Report on Form 10-Q and in its subsequent filings with the SEC. Any forward-looking statements made by the Company in this communication speak only as of the date on which they are made. The Company is under no obligation, and expressly disclaims any obligation, except as required by law, to update or alter its forward-looking statements, whether as a result of new information, subsequent events or otherwise.
Applied Digital zprovoznila další fázi Polaris Forge 1, čímž zvýšila plně provozní kapacitu kampusu na 250 MW. Akcie APLD rostou o 7 % a IREN přidává 6 % bez vlastních zpráv.
Applied Digital just hit a capacity milestone at its North Dakota campus, and the buying is spilling into a peer that released no news at all. The difference between those two rallies matters more than the gains themselves.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
A capacity milestone at Applied Digital (NASDAQ:APLD) is lifting the artificial intelligence (AI) data center group, and the buying reaches beyond the company that made the announcement. Applied Digital shares are surging 7% to $25.89 this morning. Meanwhile, IREN (NASDAQ:IREN) stock is climbing 6% to $43.03 as buyers move into the rest of the group.
To test whether a general rally explains the move, two funds offer a quick comparison. The Global X Data Center & Digital Infrastructure ETF (NASDAQ:DTCR) is up 1.51% to $27.48. The SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is also gaining 0.9% to $770.58.
Shares of Applied Digital are outpacing both funds, so a broad bid for equities doesn’t account for the scale of its gain, and IREN stock rising alongside Applied Digital shares points to investors buying the data center group together, with the Polaris Forge 1 milestone acting as the spark. That combination frames the rally as a group trade, with Applied Digital at the front.
Another Polaris Forge 1 Phase Reaches Ready for Service Ready for Service status now applies to the latest phase of a building at Applied Digital’s Polaris Forge 1 campus in Ellendale, North Dakota. Applied Digital stated that the delivery brings the campus’s fully operational capacity to 250 megawatts (MW). The campus is fully leased, and Applied Digital is contracted to deliver more capacity there at completion.
In the announcement, Applied Digital Chairman and CEO Wes Cummins stated, “Securing power is only the starting point. The real work is designing, building, commissioning, and operating the infrastructure that transforms those megawatts into usable capacity for customers.” That emphasis fits Applied Digital’s situation, since the campus was already fully leased before this capacity came online. Turning secured power into working capacity on schedule is the part of the model that lease signings alone can’t prove.
IREN Rises Without News of Its Own The gain in IREN stock stands out because the company has offered no announcement of its own to explain the move. That pattern suggests traders are treating Applied Digital’s progress as evidence for operators like IREN that convert secured power into leased AI capacity. Somebody must power, cool, and connect all that expansion. We pulled together seven of those suppliers in a free report on the AI infrastructure trade.
Applied Digital stock has a concrete catalyst behind its gain, with 250 MW now fully operational at the company’s Polaris Forge 1 campus. IREN shares, by contrast, are moving on mood alone, which leaves that advance more exposed if enthusiasm for the group cools, while behind the delivery sits Applied Digital’s fully leased campus, which ties the milestone to contracted customers.
Funding the Buildout Is the Open Question Delivery at this phase is settled, and the cost side of Applied Digital’s story now comes into focus. Building and commissioning capacity at this scale takes heavy capital, and the unresolved issue is whether Applied Digital can keep funding that pace without stressing its balance sheet. Shareholders may want to keep an eye on whether the company’s next phases arrive on schedule and how Applied Digital pays for them.
The next test for IREN stock is whether shares can hold their gain once the lift from Applied Digital’s milestone fades. Traders can watch for new announcements from IREN or its peers that would give the group a catalyst of its own. Absent company news, IREN shares could stay tied to whatever direction the group takes.
Contact [email protected] for any questions or corrections.
Key Takeaways CDW expects operating leverage and expense efficiency to improve sequentially through the second half.Gross margin fell 70 basis points as hardware infrastructure and enterprise orders gained mix.CDW expects services demand to strengthen as infrastructure projects move into implementation. CDW Corporation (CDW - Free Report) has entered the second half of 2026 with a focus on improving operating leverage and expense efficiency after delivering solid second-quarter results. The company reported second-quarter net sales of $6.6 billion, up 10% year over year, while gross profit increased 6% to $1.3 billion. Non-GAAP operating income rose 7% to $556 million, and non-GAAP earnings per share increased 12% to $2.91. However, gross margin declined 70 basis points (bps) year over year to 20.1%, reflecting a greater contribution from large hardware infrastructure opportunities related to modernization and AI readiness, particularly among enterprise customers, along with a lower relative contribution from services.
On the last earnings call, management highlighted that the gross-margin pressure was primarily a function of business mix rather than like-for-like pricing pressure. CDW maintained pricing discipline and continued to pass through price increases, while the growing mix of infrastructure products, larger-dollar orders and enterprise customers carried relatively lower margins. At the same time, netted-down revenue streams increased 16.1% and accounted for 35.9% of gross profit, up 300 bps year over year. Services grew only 1% as customers prioritized hardware and cloud investments and deployment timing affected demand, although CDW expects life-cycle and professional services activity to increase as customers move from procurement toward implementation and management.
The second half is expected to bring greater benefits from CDW’s Geared for Growth initiatives. Second-quarter non-GAAP SG&A represented 57.9% of gross profit, down 20 bps year over year and 410 bps sequentially. Management said the second-quarter improvement in operating leverage largely reflected expense discipline and broader efficiency measures, while the more significant benefits from Geared for Growth are expected to emerge in the back half. The company expects both operating leverage and its expense ratio to improve sequentially through the second half and into 2027.
For 2026, CDW expects gross profit to grow in the mid-single digits, although second-half gross margins are projected to remain below year-ago levels because of product and end-market mix. Third-quarter non-GAAP SG&A is expected to decline sequentially, helping reduce operating expenses as a percentage of gross profit both year over year and sequentially. Management also expects services demand to strengthen as current infrastructure projects progress into implementation, supporting its expectation for improving operating leverage during the second half.
Taking a Look at CDW’s CompetitorsServiceNow, Inc.’s (NOW - Free Report) margins remain under pressure as rising AI adoption and greater reliance on hyperscaler infrastructure increase costs. In the second quarter of 2026, non-GAAP total gross margin declined to 78% from 81% a year earlier, while subscription gross margin fell 250 bps to 80.5%. Despite the pressure, non-GAAP operating margin remained stable at 29.5%, supported by revenue outperformance and disciplined spending. For 2026, ServiceNow continues to target an 81% non-GAAP subscription gross margin and 31.5% operating margin. Management expects AI-driven efficiencies, including roughly $500 million in internal savings, to help offset infrastructure and integration-related margin pressures.
Accenture plc’s (ACN - Free Report) margins remained relatively stable in the third quarter of fiscal 2026, despite ongoing investments in AI, talent and acquisitions. Gross margin was 32.8%, slightly below 32.9% in the year-ago quarter, reflecting continued cost pressures from its labor-intensive delivery model and evolving AI-led services. However, operating income increased 6% year over year to $3.18 billion, while operating margin expanded 20 bps to 17% from 16.8%. SG&A expenses declined to 15.8% of revenues from 16%. Strong Managed Services growth and disciplined cost management supported profitability, although AI-driven delivery changes and higher acquisition spending could influence margins going forward.
Avnet, Inc.’s (AVT - Free Report) margin profile is improving as higher volumes, favorable mix and operating leverage support profitability. Adjusted operating margin expanded to 3.8% in the fourth quarter of fiscal 2026, up 73 bps sequentially and 129 bps year over year. Electronic Components margin reached 4.1%, while Farnell’s margin rose to 9% from 4.3% a year earlier, supported by a higher mix of on-board components. Management expects Farnell to reach double-digit margins before the end of fiscal 2027 and consolidated SG&A as a percentage of gross profit to fall below 60%. However, gross margin remains sensitive to regional mix and pricing dynamics.
Commercial Metals Company (NYSE:CMC) will release its fourth-quarter earnings report before the opening bell on Thursday, Oct. 15.
Analysts expect the Irving, Texas-based company to report quarterly earnings of $1.98 per share, up from $1.37 per share in the year-ago period. The consensus estimate for CMC’s quarterly revenue is $2.56 billion. It reported $2.11 billion last year, according to Benzinga Pro.
On Aug. 5, CMC raised its share repurchase program by $600 million.
Commercial Metals shares rose 1% to close at $62.72 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Cantor Fitzgerald analyst Dave Rochester maintained the stock with a Neutral rating and raised the price target from $30 to $31 on Aug. 19, 2026. This analyst has an accuracy rate of 59%. Citigroup analyst Benjamin Gerlinger maintained the stock with a Neutral rating and increased the price target from $29 to $32 on July 21, 2026. This analyst has an accuracy rate of 51%. Piper Sandler analyst Stephen Scouten maintained the stock with an Overweight rating and increased the price target from $33 to $36 on July 17, 2026. This analyst has an accuracy rate of 74%. Stephens & Co. analyst Matt Olney maintained an Overweight rating and raised the price target from $32 to $35 on July 17, 2026. This analyst has an accuracy rate of 69%. Keefe, Bruyette & Woods analyst Christopher Mcgratty maintained the stock with a Market Perform rating and boosted the price target from $30 to $32 on July 17, 2026. This analyst has an accuracy rate of 65%. Considering buying CMC stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Stárnutí baby boomerů a téměř zastavená nová výstavba senior housing zvyšují cenovou sílu REITů. Nejvíc z toho těží Welltower a Ventas, zatímco CareTrust nabízí nejvyšší výnos a nejsilnější krytí dividendy.
Baby boomers are turning 80 in waves while new senior housing construction has nearly stopped, and that collision of demographics and supply is reshaping how much income four REITs can realistically promise their investors.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The leading edge of the “nearly 70 million baby boomers has just begun turning 80 this year”, according to the Ventas (NYSE:VTR) chief executive, and new construction is close to a halt. Ventas executives noted “a little over a thousand starts this quarter and there’s two million people turning 80 just in 2026.” When demand rises and supply doesn’t, landlords gain pricing power, and that is the background for this edition of REIT Rent Check on senior housing and skilled nursing. September was a rough month for the group anyway. Over the past month, Ventas fell 8.5% and CareTrust REIT (NYSE:CTRE) fell 9.11%. That decline raised yields across the roster. All four names below are equity REITs that own buildings. Their dividends come from rent and operating income.
Two Ways a Senior Housing REIT Gets Paid The operator structure determines how much risk sits in each rent check. In a triple-net lease, an operator pays the REIT a fixed rent, usually with annual increases, and covers taxes, insurance and maintenance. The REIT’s risk is whether the operator can keep paying, so the number to track is rent coverage (operator EBITDAR divided by rent). In a SHOP (senior housing operating portfolio, sometimes called RIDEA) structure, the REIT owns the building and keeps the operating profit, while a manager runs the community for a fee.
That arrangement gives the REIT the full upside when occupancy and rates rise, and the full downside when costs jump. Welltower (NYSE:WELL) and Ventas lean mostly on SHOP. Omega Healthcare Investors (NYSE:OHI) and CareTrust lean mostly on triple-net. Dividend safety below is measured on FFO, AFFO or FAD (cash flow measures REITs use in place of net income), and each section names the metric it uses.
REIT Price (Oct. 1 Close) Forward Annual Dividend Forward Yield Coverage Read Welltower $226.94 $3.40 1.50% 53% of normalized FFO guidance midpoint Ventas $83.73 $2.08 2.48% 54% of normalized FFO guidance midpoint Omega Healthcare $45.23 $2.72 6.01% 84% of AFFO guidance midpoint CareTrust REIT $35.91 $1.56 4.34% approximately 76% of normalized FAD (company disclosed) Welltower Trades Yield for the Fastest Growth in Senior Housing Welltower is the largest pure-play senior housing REIT. It owns communities across the U.S., the U.K. and Canada, plus outpatient medical and post-acute assets. The SHOP segment generated $3.03B of second-quarter revenue, so Welltower gets operating profit directly. Most of that revenue comes from wealthy residents: private pay makes up 93.0% of SHOP revenue, which limits exposure to Medicaid budget fights.
SHOP same-store NOI rose 20.5% year over year, same-store occupancy climbed to 89.4% from 86.1%, and RevPOR (revenue per occupied room) grew 5.2%. SHOP expense growth was only about 0.7%, which is why flow-through margins reached the mid-60% range.
Yield and coverage: Welltower raised its quarterly dividend 15% to $0.85, its 221st consecutive quarterly dividend. At the October 1 close, that works out to a forward yield of 1.50%, the lowest on this list. On normalized FFO, the payout is very safe. Full-year guidance was raised to $6.36 to $6.44 per diluted share, and the $3.40 annualized dividend uses about 53% of the midpoint. Leverage finished the quarter at 2.99 times net debt to adjusted EBITDA.
Bull case: Welltower closed $15.5B of gross investments through the first half, including the C$4.1B Amica Senior Lifestyles deal. Much of the newly acquired product was bought at roughly 75% occupancy and about a 20% discount to replacement cost, which leaves room for occupancy gains. As management put it, “Closing an acquisition is not the culmination of the work. It is the moment the work begins.”
Risk: Growth this fast depends on outside capital. Welltower raised $3.9 billion in a single quarter through share issue, OP units and capital recycling. The stock is down 5.61% over the past month, though it is still up 23.57% year to date.
Ventas Pairs Double-Digit SHOP Growth With a Shrinking Debt Load Ventas is steering its portfolio toward SHOP. That segment produced $1.36B of second-quarter revenue, compared with $229M from outpatient medical and research and $125M from triple-net leases. Management expects SHOP to reach 60% of a $60 billion enterprise by year-end.
SHOP same-store cash NOI rose 16.3% year over year, and the U.S. portfolio grew 18%. Average occupancy gained 300 bps (U.S. SHOP gained 360 bps), RevPOR grew 5%, and cash NOI margin expanded 210 bps. Chief Executive Debra A. Cafaro framed the setup directly: “Demographic demand is strong and getting stronger as the baby boomers begin turning 80 this year. Meanwhile, new supply remains at historic lows, setting up a compelling multiyear runway for growth and value creation.”
Yield and coverage: The quarterly dividend is $0.52, up from $0.48 through 2025, and the next payment is due October 15, 2026. The forward yield is 2.48%. Normalized FFO guidance was raised to $3.85 to $3.90 per share, and the $2.08 annualized dividend takes about 54% of the $3.88 midpoint. That is a well-covered payout with room to grow.
Bull case: Net debt to further adjusted EBITDA has fallen to 4.7x from 5.6x a year earlier. Ventas also raised its 2026 investment target to $4.5B from $3B. Its U.S. senior housing portfolio stands at 87% occupied, compared with Welltower’s same-store pool near 89.4%, so Ventas has more occupancy path left before pricing power fully kicks in.
Risk: Ventas is buying at an average expected year-one yield of 6.6%. Funding those deals with stock pays off only while the share price remains strong. The stock has fallen 8.5% in a month, which makes each new share issued more dilutive.
Omega Healthcare Clears the Ultra-High-Yield Bar, With a Bankruptcy Attached Omega is mainly a skilled nursing landlord. Triple-net investments generated $324M of second-quarter revenue, while a new operating portfolio added $5.4M. Omega also makes real estate loans to operators. It is still an equity REIT whose income comes mostly from property leases. Because skilled nursing relies heavily on Medicaid and Medicare, the key number here is operator rent coverage. Trailing 12-month EBITDAR coverage improved to 1.65x from 1.55x, and operator occupancy held at 82.6%.
Yield and coverage: The quarterly dividend rose a cent to $0.68, the highest amount in the company’s recorded dividend history. The payout had been stuck at $0.67 since early 2020. The forward yield is 6.01%, just above the 6% line. Second-quarter AFFO came in at $0.83 per diluted share and FAD at $0.78, both above the quarterly dividend. Full-year AFFO guidance was raised to $3.22 to $3.26 per share, so the annualized dividend uses about 84% of the midpoint. That coverage is adequate, but the buffer is the smallest in this group.
Bull case: Taylor Pickett, the chief executive, who has announced his retirement, said “the long anticipated baby boomer aging is here and is showing up in demand for both SNFs and senior housing.” Leverage is at 3.3 times. Management also said “6-7% annualized FAD growth is eminently achievable.”
Risk: Genesis Healthcare is still in Chapter 11, with $148.5M of Omega loans outstanding. Omega’s guidance assumes Genesis keeps paying $13.3M per quarter in contractual rent. Management expects the buyer to assume the master lease on the same terms, with a closing expected by the end of 2026. If that deal changes, the 84% coverage buffer gets thin quickly.
CareTrust REIT Brings the Strongest Coverage and the Lowest Leverage CareTrust owns 628 properties with 58,775 beds/units. Most are leased triple-net. Skilled nursing rent totaled $81.2M in the second quarter and senior housing triple-net $37.1M, alongside a small SHOP book and $26.8M of interest income from loans. Leases carry 2.5% inflation-based increases. Stabilized EBITDARM coverage stands at 3.21x for skilled nursing and 2.16x for senior housing, with 100% rent and interest collection. Stabilized occupancy is 83.9%.
Yield and coverage: The $0.39 quarterly dividend, paid next on October 15, 2026, yields 4.34%. CareTrust says the dividend represents approximately 76% of normalized FAD. Guidance calls for normalized FAD of $2.01 to $2.04 per share, up 15.1% at the midpoint. The dividend has increased from $0.29 in 2024 to $0.335 in 2025 and to its current level.
Bull case: CareTrust closed $899.6M of investments in the second quarter at an 8.9% combined stabilized yield, its biggest quarter outside M&A. Net debt to run-rate EBITDA was just 1.0 times, the company has no debt due dates before 2028, and Moody’s upgraded it to investment grade. CEO Dave Sedgwick said “there has simply never been a more exciting time for CareTrust.”
Risk: The loan book is growing, and it already produced a cost. CareTrust recorded a $4.67M provision for loan losses in the quarter. Loans carry operator credit risk that a deed to a building does not, so watch reserve levels as the company deploys more capital this way.
Where the Rent Checks Look Safest CareTrust offers the best balance in this group: a 4.34% yield, a payout of roughly 76% of FAD, and the strongest coverage. Welltower and Ventas pay smaller yields but cover their dividends about twice over on FFO, and their SHOP growth is where future increases will come from. Omega pays the most, and the Genesis bankruptcy outcome will determine whether that 6% yield holds.
Contact [email protected] for any questions or corrections.
Rostoucí výnosy amerických státních dluhopisů srazily pět dividendových titulů z energetiky a utilit. Nejlépe chráněné dividendy mají podle článku Kinder Morgan a Duke Energy.
Rising Treasury yields just knocked five pipeline and utility stocks to levels that have income investors asking whether the selloff created a buying window or a warning sign worth heeding.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The 10-year Treasury yield rose from 4.77% on Sept. 3 to 5.29% on Sept. 30, and income stocks sold off with it. That pushed down prices on five dividend payers that share one income angle: fee-based pipeline contracts and regulated power rates that fund growing dividends, while capital spending shifts toward LNG exports and data-center electricity demand. All five yields below sit under the Treasury, so the case for each depends on dividend safety and growth. Here is how the payouts hold up.
Williams Companies: Pipeline Payout Raised Every Year Since 2018 Williams Companies (NYSE:WMB | WMB Price Prediction) pays an annualized forward dividend of $2.10 per share. At $69.30, that works out to a forward yield of about 3.03%. Shares slipped 7.22% over the past month, and they are still up 17.8% year to date.
Dividend Safety Check The quarterly dividend went from $0.30 in 2017 to $0.34 in 2018, and Williams has raised it every year since. The latest step was from $0.50 to $0.525 in 2026. For a pipeline company, cash flow says more about coverage than earnings do. Williams guided to 2026 AFFO of $6.085 billion to $6.315 billion, while the dividend costs roughly $2.57 billion a year. At the midpoint, AFFO covers the payout about 2.4 times. Measured against trailing EPS of $2.55, the payout ratio is about 82%. Management expects pro-forma leverage of 3.75x debt to EBITDA.
Bull Case Williams raised its 2026 adjusted EBITDA guidance to $8.3 billion to $8.5 billion after agreeing to buy Momentum Midstream for up to $5.5 billion. The deal adds more than 4,000 miles of Haynesville pipe. Management also raised its long-term EBITDA growth target to 11% plus compound annual growth through 2030. On the August call, an executive said: “We do feel well-positioned to exceed 11%.” Phase one of its Socrates power project began delivering 200 megawatts to a data-center customer, and management calls the years ahead “the decade of pipe and power.” Analysts are bullish: 22 of 24 rate it a buy or strong buy, with a consensus target of $85.46.
Risk to Weigh Growth is expensive. Williams plans $7.3 billion to $7.9 billion of 2026 growth capex. Second-quarter capex of $1.834 billion was higher than operating cash flow of $1.376 billion. The Momentum deal also includes $2 billion of equity, which adds shares. At a forward P/E of 27, it is the most highly valued stock on this list.
Kinder Morgan: Highest Yield on the List, Backed by Free Cash Flow Kinder Morgan (NYSE:KMI) pays $1.19 a year on an annualized basis. At $30.42, the forward yield is about 3.91%, the highest of these five. Shares fell 5.23% over the past month. CNBC’s Jim Cramer supported the stock in his Sept. 30 lightning round.
Dividend Safety Check Second-quarter free cash flow was $978 million, compared with a quarterly dividend spending of roughly $662 million. That covers the payout about 1.48 times. Net debt was 3.6x adjusted EBITDA, the low end of the company’s target range, and Moody’s upgraded Kinder Morgan to Baa1 earlier this year. Against the 2026 budget of $1.36 in adjusted EPS, the payout ratio is 87.5%. Management expects to beat that EPS budget by more than 12%. The dividend has gone up in every year from 2021 through 2026, most recently to $0.2975 per quarter.
Bull Case Natural gas transport volumes rose 7% year over year. Kinder Morgan’s project backlog stands at $9.6 billion, with 92% in natural gas and more than 60% tied to power generation and local distribution demand. Second-quarter adjusted EPS of $0.37 beat the $0.3128 estimate, and adjusted EBITDA grew 12% to $2.20 billion.
Risk to Weigh Kinder Morgan has cut its dividend before. The quarterly payout dropped from $0.51 in late 2015 to $0.125 in 2016. Recent raises have been small: the latest increase was 2%. Refined products volumes also fell 5%, and crude and condensate volumes fell 16%.
Duke Energy: Carolinas Utility Near Its 52-Week Low Duke Energy (NYSE:DUK) pays an annualized $4.34 per share. At $113.49, the forward yield is about 3.82%. The stock trades close to its 52-week low of $110.99, well under the $136.11 analyst target.
Dividend Safety Check The quarterly dividend rose to $1.085 from $1.065 in August, and Duke’s records show regular quarterly payments going back to 1999. The payout is about 65% of trailing diluted EPS of $6.64, the most comfortable coverage of the three utilities here. Like most regulated utilities, Duke spends more on its grid than it generates in cash, so earnings coverage and access to capital matter more than free cash flow. Duke closed $5.3 billion of strategic transactions in the first quarter, which strengthened its funding position.
Bull Case Duke reaffirmed 2026 adjusted EPS guidance of $6.55 to $6.80 and targets 5% to 7% annual adjusted EPS growth through 2030. It has signed 7.6 GW of economic-development projects under electric service agreements, and retail electric customers grew 1.4%. Second-quarter adjusted EPS of $1.43 beat the $1.3062 estimate. At a forward P/E of 16, Duke is the cheapest utility on this list.
Risk to Weigh Interest expense and depreciation are rising as the asset base grows. Coal-ash remediation costs remain uncertain, and data-center load could come in below expectations.
Southern Company: Data Centers Are Lifting Commercial Power Sales Southern Company (NYSE:SO) pays an annualized $3.04 per share. At $83.20, the forward yield is about 3.65%. Shares are down 9.34% over the past year and sit close to the 52-week low of $81.69.
Dividend Safety Check Southern raised its quarterly dividend in every year from 2021 through 2026, from $0.64 to the current $0.76. The payout is about 73% of trailing EPS of $4.15, which is normal for a regulated utility. Earnings power is growing: second-quarter GAAP net income rose 33.41% to $1.174 billion.
Bull Case Commercial electricity sales rose 7.3% on data-center demand, and wholesale sales climbed 9.2%. Adjusted EPS of $1.13 beat the $1.00 estimate. With Vogtle fully in service, Georgia Power has a larger rate base to earn on. The forward P/E of 17 is below the trailing figure of 20, which means analysts expect earnings to grow.
Risk to Weigh First-quarter interest expense reached $778 million, up from $714 million, and Southern Power expects about $205 million in remaining pre-tax repowering charges in 2026. Analysts are cautious too: 13 rate the stock a hold and 3 rate it a sell or strong sell.
OGE Energy: Ex-Dividend Date Is Days Away OGE Energy (NYSE:OGE) pays an annualized $1.715 per share. At $45.67, the forward yield is about 3.76%. Its newly raised $0.42875 quarterly dividend goes ex-dividend on Oct. 5 and will be paid on Oct. 30.
Dividend Safety Check OGE’s records show a dividend increase every year since 2015, when the quarterly payout was $0.25. The annualized dividend equals about 71% of 2026 EPS guidance of $2.43. On the July call, CFO Chuck Walworth said: “We have completed all planned financing activities for 2026 and continue to target credit-supportive metrics including maintaining FFO to debt of approximately 17% over the planning horizon.”
Bull Case OGE set a new all-time peak load of more than 6,800 megawatts. It filed a Google special contract in Oklahoma on May 1 and has six or seven large-load negotiations underway. Its proposed large-load tariff requires data centers to pay 100% of their grid connection costs upfront and sign a minimum 15-year commitment, which protects existing ratepayers. OGE expects to add 550 megawatts of capacity in 2026.
Risk to Weigh Dividend growth has nearly stalled. The latest raise was about 0.88%. Weather also affects results: first-quarter net income fell 19.94% after a mild winter. With a market cap of $9.43 billion, OGE is also much smaller and less diversified than Duke or Southern.
Five Payouts Funded by America’s Growing Power Demand The jump in Treasury yields to 5.29% drove these five stocks lower, while the contracts and rate bases that pay their dividends stayed intact. Williams and Kinder Morgan move the natural gas that LNG terminals and new power plants need. Duke, Southern, and OGE sell the electricity that data centers and new factories use. Kinder Morgan’s free cash flow coverage and Duke’s 65% payout ratio stand out as the strongest dividend protection in the group, while Williams offers the fastest growth behind its payout.
The data-center power build is the thread tying these five payouts together, and the chip names are only part of that trade. We featured seven suppliers on the power, cooling, and networking side of the AI expansion in a free report you can download here: 7 Stocks Powering the AI Boom (That Aren’t Chipmakers).
Contact [email protected] for any questions or corrections.
Nike klesá o 8 % po zklamání z tržeb, slabém výhledu a oznámení propouštění. Tržby za fiskální 1. čtvrtletí 2027 činily 11,21 mld. USD, pod odhadem 11,32 mld. USD.
Nike is cratering on earnings while rivals Lululemon and On Holding barely flinch, raising a pointed question about whether the sportswear giant is fighting a problem unique to itself or simply the first to feel an industry-wide reckoning.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Nike (NYSE:NKE | NKE Price Prediction) is taking a company-specific hit to its turnaround story, while the rest of athletic apparel holds largely steady. Shares of Nike are down 8% to $32.34 in morning trading after fiscal 2027 first-quarter results showed a revenue miss, a weak outlook and job cuts. Nike stock was already trading near its 52-week low.
Meanwhile, shares of Lululemon (NASDAQ:LULU) are nearly unchanged at $95.85. On Holding (NYSE:ONON) stock trades at $30.18, also practically unchanged and showing no signs of contagion.
The Consumer Discretionary Select Sector SPDR ETF (NYSEARCA:XLY) is unchanged at $108.81, showing the damage is confined to Nike. The SPDR S&P 500 ETF Trust (NYSE ARCA:SPY) is up 1% to $771.34, so the broad equities market is holding up well.
Nike carries a weight of just 1.2% in the XLY sector fund, so the drop barely moves it.
Revenue Miss and Job Cuts Drive Nike Lower Nike’s quarterly revenue came in at $11.21 billion, missing the $11.32 billion consensus and falling 4.3% year over year. Diluted earnings came in at $0.48 per share, ahead of expectations, on a wider gross margin.
The heavier blow came from Nike’s fiscal 2027 outlook, which calls for revenue to decline by a high-single-digit percentage.
Nike also unveiled Pace, an overhaul targeting $2.5 billion in cumulative savings through fiscal 2031 at a cost of $1 billion in pre-tax charges, mostly employee-related. Chief Executive Officer Elliott Hill wrote in a letter to employees: “This work will result in fewer roles across Nike, and I want to acknowledge that news like this creates uncertainty. I don’t take that lightly.” Decisions on affected roles are expected to begin next calendar year and beyond.
Lululemon and On Holding Hold Their Ground Lululemon stock is down 54% year to date, a slide that deepened after the company cut its full-year guidance in September. During the earnings call, Lululemon executives traced the company’s weakness to brand sentiment and traffic, stating, “We’re not pointing to macro specifically as a key issue.” That framing helps explain why Nike’s warning leaves Lululemon steady.
On Holding stock is down 35% year to date, yet its recent results look far healthier than Nike’s. Net sales rose 13.5% in the latest quarter, while gross margin expanded to 65.4%, moving management to lift its full-year floor to at least 65%. That momentum gives it little reason to track Nike lower.
Dick’s Sporting Goods (NYSE:DKS) offers a retail-channel read. In August, the retailer’s chief executive cited “growing pressure across portions of the athletic footwear and apparel marketplace,” while Dick’s executives described running and performance product as healthy. Nike’s call reflected that split, with its performance business growing at a high-single-digit pace as Nike Sportswear declined by a low-double-digit percentage.
Nike’s Investor Day Shapes the Next Move Nike stock is now down 48% year to date. Hill stated that Nike has “more work to do in NIKE Sportswear, Jordan Brand and Greater China,” and management expects pressure there could remain into fiscal 2028. More detail on Pace and longer-term targets is due at its investor day in November.
Nike still has supports, including its performance business, wider gross margin and quarterly dividend of $0.41 per share, though the dividend offers limited buffer in a multiyear turnaround. Investors should size holdings carefully given falling revenue guidance and Pace savings that mostly arrive in fiscal 2029 and 2030.
Lululemon shareholders should weigh the company’s lowered full-year outlook, which calls for revenue to fall 5% to 7%. On Holding looks stronger, though Section 301 tariffs imposed in July could lift costs, so stakes there may warrant moderation. Dick’s remains a useful channel check on how quickly Nike’s lifestyle inventory sells.
Contact [email protected] for any questions or corrections.
Amphenol ve 2. čtvrtletí zvýšil tržby divize Communications Solutions o 85 % na 5,38 miliardy USD; tato divize táhne růst díky poptávce po AI infrastruktuře. Pro 3. čtvrtletí čeká další středně desítkový mezikvartální růst.
Key Takeaways Amphenol's Communications Solutions revenues surged 85% year over year to $5.38 billion.AI-related products drove virtually all sequential IT datacom growth, with Q3 gains expected.CommScope is now expected to generate $4.6 billion in 2026 sales, up from $4.1 billion. Amphenol (APH - Free Report) is benefiting from robust growth in its Communications Solutions segment, supported by accelerating demand for high-speed interconnect products used in AI infrastructure and contributions from its acquisition program. In the second quarter of 2026, Communications Solutions revenues surged 85% year over year to $5.38 billion and increased 42% organically. The segment accounted for roughly 62% of Amphenol’s total revenues, making it the company’s largest growth engine. The year-over-year growth was primarily driven by outsized IT datacom growth, particularly AI-related applications, alongside strength in industrial, mobile devices and automotive markets.
AI infrastructure remains the biggest growth engine and is helping the company fight off competition from the likes of TE Connectivity (TEL - Free Report) and Bel Fuse (BELFB - Free Report) . IT datacom represented 43% of Amphenol’s second-quarter sales, with revenues rising 89% year over year and 63% organically. Sequentially, IT datacom revenues climbed 22%, with virtually all of the sequential growth stemming from AI-related products. APH expects another mid-teens sequential increase in the third quarter of 2026, supported by accelerating investments in AI data centers and stronger enterprise and cloud demand for traditional IT datacom equipment.
Amphenol’s broad portfolio across high-speed copper, fiber-optic and power interconnects is strengthening its exposure to the AI buildout. The company noted that customers increasingly require all three technologies as computing architectures become denser and more power-intensive. The CommScope acquisition is further strengthening Communications Solutions, particularly in optical interconnects. CommScope generated slightly more than $1.2 billion in second-quarter sales, while its IT datacom business nearly doubled year over year. Amphenol now expects CommScope to generate $4.6 billion of sales in 2026, up from its earlier expectation of $4.1 billion.
Higher Communications Solutions revenues are also supporting profitability. Segment operating margin expanded to 33.6% in the second quarter of 2026 from 30.6% a year earlier, benefiting primarily from operating leverage on significantly higher organic volumes. This combination of accelerating AI connectivity demand, rising optical exposure through CommScope and strength across several other end markets should continue to support Communications Solutions as an important growth driver for Amphenol.
For the third quarter of 2026, APH expects sales of $9.3-$9.4 billion. The range implies year-over-year growth of 50-52%, assuming current market conditions and constant exchange rates. Adjusted earnings are projected between $1.40 and $1.42 per share, indicating growth of 51-53% from the prior-year quarter.
How Rivals Stack Up Against APHTE Connectivity is challenging Amphenol across high-speed data and power connectivity by expanding its exposure to AI infrastructure. TEL’s Digital Data Networks (DDN) business is benefiting from hyperscaler investments in GPU clusters, with year-to-date DDN orders up more than 70%. In the third quarter of fiscal 2026, DDN sales increased 34% year over year, supported by demand for high-speed copper connectivity, while higher-voltage architectures are expanding opportunities in power connectivity. TE Connectivity estimates that power already represents roughly one-third of its DDN business, giving it exposure to both data transmission and rising power requirements inside AI racks.
Bel Fuse is a smaller but growing challenger. The company’s Industrial Technology & Data Solutions (ITDS) segment includes power supplies, fuses, integrated connector modules and transformers used in networking, data centers and AI applications. In the second quarter of 2026, ITDS revenues jumped 31.1% year over year to $100.2 million, while Data Solutions revenues surged 55%, aided by the beginning of a ramp tied to high-performance computing project wins. The dataMate acquisition also expanded Bel Fuse’s Data Solutions portfolio.
APH’s Share Price Performance, Valuation & EstimatesAmphenol’s shares have surged 24.8% year to date, outperforming the broader Zacks Computer & Technology sector’s return of 21.8%.
APH Stock’s Price Performance
Image Source: Zacks Investment Research
Amphenol shares are trading at a premium, as suggested by a Value Score of D. In terms of the forward 12-month price-to-earnings (P/E), APH is trading at 27.47X, higher than the broader sector’s 19.95X.
APH Stock is Overvalued
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Amphenol’s 2026 earnings is pegged at $2.66 per share, up three cents over the past 30 days. The figure indicates a 59.3% jump year over year.
APH currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Paychex beat earnings estimates for the fourth straight quarter, then watched its stock crater anyway as investors zeroed in on a single line item that raised uncomfortable questions about what it actually costs to keep shareholders happy.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Paychex (NASDAQ: PAYX | PAYX Price Prediction) beat on the top and bottom lines on Wednesday, Sept. 23, but the stock had its worst session in more than a year. Shares fell 7.18% intraday to $106.31, and investors are focused less on the beat and more on the check that got written to shareholders.
More than a week later, that loss has increased to 5%, dragging the stock’s year-to-date loss down to 7.71%, and its one-year loss to nearly 21%. Why? Paychex sent $424.1 million out the door in dividends against $429.7 million of net income. That is almost the entire quarter.
A Beat With a Very Expensive Payout Adjusted EPS came in at $1.34 versus $1.32 consensus, the fourth consecutive quarter of beating EPS estimates. Revenue of $1.63 billion grew 5.9% year over year. GAAP operating margin expanded to 38.0% from 35.2% as Paycor integration costs faded.
PEO and Insurance Solutions was the standout, up 12% on strong worksite employee growth. Management raised full-year PEO growth guidance to 7% to 8% and interest on client funds to $200 million to $210 million.
Cash Line That Spooked Investors Operating cash flow was $413.5 million, down 42.44% year over year, which management attributed to the timing of client and corporate tax payments. Cash and equivalents fell to $600.9 million, down 25.7% year over year. Cash used in financing was $906.6 million. Fair caveat: fiscal Q1 is Paychex’s seasonally lightest quarter, and float-driven working capital swings are normal at a payroll processor. You’ll want to see full-year coverage in the 10-Q before drawing hard conclusions about sustainability.
Key Figures Adjusted EPS: $1.34 vs. $1.32 expected Revenue: $1.63 billion, up 5.9% Operating margin (GAAP): 38%, up from 35.2% Net income: $429.7 million, up 11.96% Operating cash flow: $413.5 million, down 42.44% Dividends paid: $1.19 per share, $424.1 million total The dividend was raised roughly 10% to $1.19 earlier this year. The stock’s forward yield sits above 4%. That is the number income investors are buying (the whole point of a dividend ladder is never having to sell a share to pay the bills, and we walked through how to build one in a free guide here).
Gibson Points to AI and Advisory CEO John Gibson said Paychex “delivered a solid start to total revenue growth in fiscal 2027, with double-digit PEO and Insurance Solutions revenue and EPS growth underscoring the strength of our advisory solutions.” On AI, he pointed to “compelling early adopter results from our award-winning WISE engine and the introduction of WISE Hire, our agentic recruiting solution.” CFO Bob Schrader added, “This quarter we returned $424 million to shareholders through cash dividends.”
What Income Investors Should Watch Next Full-year adjusted EPS growth guidance held at 7% to 9%, so the annual math still works on paper. I’d keep an eye on Q2 revenue growth, which management pegged at approximately 4% against a tough compare, and on operating cash flow trends once the 10-Q lands. Jim Cramer previewed the quarter saying Paychex had a “full head of steam.” PAYX’s performance over the past week disagrees.
Contact [email protected] for any questions or corrections.
Exelon čeká na rozhodnutí regulátora k plánu ComEd za 15,3 miliardy USD do 15. prosince; zamítnutí by mohlo zpomalit růst dividendy nebo přinutit k vydání nových akcií.
Exelon's dividend yield has climbed to its most attractive level in years, but a single regulatory decision this December could determine whether that income stream grows, stalls, or forces a flood of new stock onto the market.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Exelon (NASDAQ:EXC | EXC Price Prediction) trades at $40.35. That is down 6.82% over the past month and 7.05% over the past year, and the slide has raised the dividend yield to 4.07%. When a yield rises because the price fell, income investors need to know what pays the $1.68 forward annual dividend.
A Wires-Only Business Paid by Regulators Exelon is a pure regulated wires company. It runs six regulated transmission and distribution utilities: ComEd, PECO, BGE, and PHI’s Pepco, Delmarva Power and Atlantic City Electric. Regulators approve a “rate base” (the value of poles, wires, and substations) and allow a set return on it. When Exelon builds more grid and wins approval, earnings grow. Fuel prices and recessions matter far less than for most companies, so cash flow is unusually predictable.
In 2025, Exelon earned a 9.7% operating ROE, and it targets 9-10%. Its rate base is expected to grow from $64.6B in 2025 to $87.4B in 2029, a 7.9% CAGR. That growth supports guidance for 5% to 7% annual EPS growth through 2029.
Coverage Sits Right on Target Trailing dividends of $1.64 against EPS of $2.74 yield a payout ratio of about 60%. The forward dividend uses about 59% of the midpoint of 2026 guidance, which is $2.81-$2.91.
Company Yield Trailing Payout Forward P/E Exelon 4.07% 60% 14 Duke Energy (NYSE:DUK) 3.73% 64% 16 Southern Company (NYSE:SO) 3.57% 72% 17 Exelon offers the highest yield and lowest payout ratio of the three, trading at the cheapest multiple. Its track record is shorter. The quarterly dividend fell from $0.3825 in 2021 to $0.3375 in 2022 after the generation spinoff, then rose to $0.36, $0.38, $0.40 and $0.42. Management guides for about 5% annual dividend growth.
Borrowed Money Fills the Capex Gap In 2025, operating cash flow of $6.25B covered dividends of $1.62B about four times over but fell short of capex of $8.53B. Financing brought in $2.53B. Interest expense grew from $1.73B in 2023 to $2.13B in 2025. Exelon needs $3.4B of equity through 2029, with ~37% already priced. Management said in July:
“Maintaining a strong balance sheet is core to our strategy and essential to funding the investments needed to deliver safe, reliable, and affordable service for our customers.”
State Regulators Hold the Key Credit pressure is showing. Moody’s placed PECO under review for downgrade, and S&P downgraded BGE. Exelon dropped a Pennsylvania rate case. ComEd’s $15.3 billion grid plan faces an order by December 15th.
“If critical work is deferred for too long, customers ultimately pay the price through more outages, more costly repairs, and higher long-term costs.”
Data center demand gives Exelon room to grow. After speculative projects were removed, the pipeline fell to 36 gigawatts from 43. Signed agreements cover four gigawatts, backed by a billion dollars of collateral. Management added: “We have not put in speculative projects.”
One Scenario Puts the Payout at Risk The dividend is durable. Regulated rate base growth pays for it, and the payout ratio is at target. The danger is a holding-company downgrade if Illinois or Pennsylvania regulators deny cost recovery, earned ROE falls below 9%, and interest costs keep rising. Exelon targets credit metrics of about 14%, leaving 100-200 bps of room above downgrade levels. If that buffer goes away, Exelon would slow dividend growth or issue much more stock. The ComEd order on December 15 is the first test.
Contact [email protected] for any questions or corrections.
Rapid7 spustila Rapid7 Intelligence, jednotný AI engine pro přechod od reaktivního monitoringu k proaktivní prevenci útoků. Firma zároveň uvedla, že její výzkumníci odhalili modulární linuxový malware mířící na telekomunikační a síťová edge zařízení.
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today, Rapid7, Inc. (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, announced the launch of Rapid7 Intelligence, a unified engine designed to transform enterprise threat defenses from reactive monitoring to proactive prevention. By combining threat intelligence, vulnerability research, and the legacy of Rapid7 Labs, Rapid7 Intelligence transforms insights on attacker behavior into AI-powered action to help organizations anticipate and disrupt attacks.
Indicators Expire. Behavior Doesn't: Defense for the Agentic Era.
Building on Rapid7 Labs’ 13-year legacy, Rapid7 Intelligence turns attacker behavior into scalable protection faster than traditional vendors reliant on static indicators. With AI compressing exploitation windows to minutes—and 8,539 critical vulnerabilities tracked in Q2 alone—attackers are leveraging automation to scale phishing, reconnaissance, and script development. Rapid7 Intelligence monitors these threats in real time to deliver actionable, expert-validated insights that keep defenders ahead.
"Static threat intelligence isn't completely dead—it's just sitting in standard dashboards doing what it's always done, giving organizations a false sense of security while autonomous threat agents burn down their perimeters," said Christiaan Beek, Vice President of Rapid7 Intelligence. "The real differentiator isn't hoarding more raw feeds; it's having curated, vetted intelligence focused relentlessly on true signals rather than waiting around for alerts to trigger after the damage is done. Rapid7 Intelligence isn't built to generate another 50-page PDF report for security teams to ignore; it aggressively converts real-time operational adversary insight into a proactive, preemptive shield."
Rapid7 Intelligence in Action: Behavioral Correlation Exposes a Hidden Linux Malware Ecosystem
A concrete illustration of Rapid7 Intelligence's power is a new finding from Rapid7 researchers, who uncovered a modular Linux malware ecosystem—spanning new BPFDoor variants, BPF Rekoobe, droppers, and AVERAT implants—actively targeting telecom and network-edge devices.
Researchers identified two campaigns linked by a common focus on the network edge. Rapid7 Intelligence analyzed their shared behaviors, uncovering an emerging pattern: using SMTP to blend into the victim’s DMZ, target mail security appliances, and maintain long-term access.
New BPFDoor variants indicate the malware family is evolving into an ecosystem where each sample is tailored to the telco plane (control, management, and data plane) it targets, and where threat actors know exactly what software is adopted at each layer.
Rapid7 Intelligence will continue tracking and disrupting tactics like this to keep defenders ahead of attackers.
Expert-Led, Actionable Intelligence
To continuously power research like this and help defenders stay ahead of emerging threats, Rapid7 Intelligence delivers:
Immediate Protective Force: Frontline intelligence bypasses legacy research lags, flowing directly into Rapid7 products, MDR, and Exposure Management to neutralize adversary infrastructure before attacks execute.Unified Intelligence Engine: Threat intelligence, vulnerability analysis, and engineering inside the products customers already run, instead of a report they have to translate into action themselves.Uncompromised Community Arsenal: Building on the legendary foundation of Metasploit and Rapid7 Labs, critical advisories, vulnerability research and exploitation insights remain open, ensuring the industry stays capable of pushing back.
“In a world of infinite telemetry and automated attacks, playing defense with traditional tools is an exercise in futility,” said Mel Stone, Chief Global Services Officer at Rapid7. “Rapid7 Intelligence shifts the balance of power. By fusing machine-scale observation with frontline human expertise, we turn raw threat data into immediate, actionable intelligence—empowering security teams to disrupt adversaries before they establish a foothold.”
To learn more about Rapid7 Intelligence, visit here.
About Rapid7
Rapid7, Inc. (NASDAQ: RPD) is a global leader in AI-powered managed cybersecurity operations, trusted to advance organizations’ cyber resilience. Open and extensible, the Rapid7 Command Platform integrates security data, enriching it with AI, threat intelligence, and 25 years of expertise and innovation to reduce risk and disrupt attackers. As a recognized leader in preemptive managed detection and response (MDR), Rapid7 unifies exposure and detection to transform the cybersecurity operations of more than 11,500 customers worldwide. For more information, visit our website, check out our blog, or follow us on LinkedIn or X.
Media Contact
Christine Nurnberger
SVP Global Marketing and Growth [email protected]
Rapid7 Investor Contact
Christopher Keenan
Vice President, Deputy General Counsel [email protected]
Teradyne ve 2. čtvrtletí 2026 zvýšil tržby z testování pamětí na rekordních 212 mil. USD, už třetí čtvrtletí po sobě nad 200 mil. USD. Firma navíc uvedla Magnum E2 pro LPDDR6, DDR6, GDDR7 a NAND.
Key Takeaways Teradyne's memory revenues hit a record $212M in Q2 2026, its third straight quarter above $200M. Magnum E2 supports LPDDR6, DDR6, GDDR7 and NAND, combining memory and logic testing on one platform. TER expects the 2026 memory test TAM to be more than 40% larger than 2025 due to HBM, DRAM and NAND growth. Teradyne (TER - Free Report) is benefiting from rising demand for advanced memory testing, supported by strong high-bandwidth memory (HBM), DRAM, and NAND requirements tied to artificial intelligence (AI) infrastructure. The company’s expanding memory test portfolio, led by Magnum platforms, strengthens its competitive positioning in the broader semiconductor test-equipment market against KLA (KLAC - Free Report) and Cohu (COHU - Free Report) . Teradyne noted that Magnum testers combine memory and logic-test capabilities, providing memory manufacturers with attractive swing-tool flexibility.
Memory has emerged as an important growth engine for Teradyne. In the second quarter of 2026, memory revenues reached a record $212 million, marking the third consecutive quarter above $200 million. Growth was driven by robust demand for HBM and DRAM test solutions, as well as a recovery in NAND. Memory book-to-bill exceeded 2, indicating solid demand visibility. Management expects the 2026 memory test TAM to be more than 40% higher than 2025, supported by HBM, DRAM and NAND growth.
Further expanding its memory test portfolio, Teradyne recently launched Magnum E2, a next-generation high-speed memory test system designed to address growing test requirements driven by artificial intelligence and high-performance computing. Built on the company’s Near-DUT Test architecture, Magnum E2 supports advanced DRAM and flash interfaces, including LPDDR6, DDR6, GDDR7 and NAND flash. The platform offers higher parallelism, improved signal integrity and support for NRZ, PAM3 and PAM4 signaling. It also combines memory and logic testing on a single platform, helping manufacturers simplify testing while supporting qualification through high-volume production.
Rising memory bit production and technology transitions such as HBM3 to HBM4, DDR5 to DDR6 and next-generation flash should further increase test requirements, supporting Teradyne’s ability to expand its memory-testing footprint. Management expects memory revenues to grow in the second half compared to the first half.
How Competitors Fare Against TERTeradyne is facing stiff competition from companies such as KLA and Cohu. Both companies are expanding their footprint in the semiconductor industry.
KLA is benefiting from strong semiconductor demand, driven by accelerating investments in AI infrastructure, leading-edge foundry/logic, memory and advanced packaging. In the fourth quarter of fiscal 2026, revenues reached a record $3.66 billion, increasing 15% year over year and 7% sequentially. Management attributed the performance to rising AI infrastructure investments and greater process-control intensity across memory and advanced packaging.
Cohu’s improving semiconductor test demand and expanding exposure to AI computing, HBM inspection and software remain noteworthy. Growth in AI workloads is driving demand for HBM, and Cohu has established a position in this market through its Neon inspection platform. Cohu is extending its Neon inspection platform across HBM3, HBM4 and HBM4E production while investing in HBM5 and later generations.
TER’s Share Price Performance, Valuation and EstimatesTeradyne shares have surged 114.8% year to date, outperforming the Zacks Computer & Technology sector’s 22.4% growth and the Zacks Electronics - Miscellaneous Products increase of 43%.
TER Stock Performance
Image Source: Zacks Investment Research
TER stock is trading at a premium with a forward 12-month Price/Sales of 11.18X compared with the Electronics - Miscellaneous Products industry’s 7.74X. TER has a Value Score of D.
TER Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings is pegged at $9.11 per share, which has been unchanged over the past 30 days. This suggests 130.05% year-over-year growth.
Teradyne currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Integra LifeSciences oznámila získání navrhovaného sedmiletého zajištěného úvěru Term Loan B v objemu 600 milionů USD. Prostředky mají refinancovat stávající dluh a prodloužit splatnosti.
PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of a proposed $600 million seven-year Senior Secured Term Loan B as part of a broader refinancing transaction.
The Company intends to use the net proceeds from the Term Loan B, together with other sources of financing, to refinance certain of its existing indebtedness and pay associated fees and expenses.
“This transaction allows us to refinance our existing debt, extend maturities and maintain financial flexibility. It positions us well as we continue to focus on disciplined capital allocation and deleveraging,” said Lea Knight, Executive Vice President and Chief Financial Officer.
The proposed financing is expected to be completed in conjunction with a refinancing of the Company’s existing capital structure, subject to market and other customary conditions. There can be no assurance as to whether or when the financing will be completed, or as to the final size, terms, or pricing of the transaction.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the proposed financing transaction, expected use of proceeds, capital structure, liquidity, leverage and financial flexibility. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described. Integra undertakes no obligation to update any forward-looking statements except as required by law.
Viking Therapeutics po silných výsledcích studie pro lék VK2735 emitovala nové akcie a nyní se obchoduje pod emisní cenou 35 USD. Rozředění sníží zisk na akcii zhruba o 7,2 %.
Viking Therapeutics (VKTX -6.41%) stock soared after the release of excellent top-line results from a maintenance study of its weight-loss drug VK2735, and the company promptly moved to ultimately raise $575 million via a supplementary public offering of common stock ($316.2 million worth at $35) and $258.8 million in convertible senior notes. However, the stock now trades below the $35 price of this latest common equity offering. Is it worth buying?
On balance, the answer is: If you were bullish on the stock before the top-line results came out, it makes sense to buy it now, too.
Image source: Getty Images.
Let's run some simple numbers. At the time of writing, Viking's stock is up only 8.4% from the day before the results announcement. However, the share count before the stock offering was 116.6 million, and the company closed on another 9 million shares. The increase in share count dilutes existing shareholders, and you can pencil in a rough reduction in earnings per share of about 7.2%, or 0.928 of its previous level.
However, the share price rose 8.44%, so earnings per share per dollar invested at the current share price have also changed. You can calculate this by dividing 0.928 by 1.084 (the increased share price), which gives 0.856, a 14.4% reduction.
In plain English, assuming the same earnings, the earnings yield per dollar invested at today's price will be 14.4% lower.
Premium Feature
Moneyball Superscore
69/100
Today's Change
(
-6.41
%) $
-2.09
Current Price
$
30.51
So is Viking Therapeutics stock a buy? While the top-line results were excellent, they didn't include the oral pill (which will come in the second part of the trial), but they were good enough to somewhat de-risk maintenance dosing with injectable VK2735. That's a major plus in itself and justifies the de facto 14.4% loss in earnings power per dollar (assuming unchanged earnings) for investors, both before and after the results release and the subsequent common stock offering.
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy.
Panmure Liberum ponechal u Landsec doporučení koupit a cílovou cenu 710 p po dohodě o koupi nákupního centra Metrocentre za 516 milionů liber v hotovosti. Transakce má být dokončena do konce října, financovaná zhruba 500milionovým navýšením kapitálu a stávajícími úvěrovými zdroji.
Panmure Liberum has maintained its 'buy' rating on Land Securities Group PLC (LSE:LAND), the property investment company, with a target price of 710p, after the company agreed to acquire the Metrocentre shopping centre in Gateshead.
Landsec has exchanged contracts to buy 100% of Metrocentre for £516 million in net cash consideration, funded through a roughly £500 million equity raise and existing debt facilities.
The equity raise will also partly fund a further £100 million acquisition of interests in Landsec's existing retail portfolio.
Metrocentre generates £41 million of in-place net rental income, implying a net initial yield of 7.9%, with Landsec expecting a low double-digit unlevered internal rate of return.
The broker said it saw around 40 basis points of near-term yield upside from efficiencies across Landsec's wider property platform.
Metrocentre ranks among the UK's ten largest shopping centres, spanning 1.86 million square feet of retail space plus a further 200,000 square feet of retail park, with 282 stores and 95% occupancy.
The centre attracts more than 16 million visitors a year and generates around £650 million in annual retail sales, with tenants including Apple, Zara, Marks & Spencer and Primark.
Completion is expected by the end of October, subject to the dissolution of a legacy Intu entity and bondholder consent, with more than 80% of bondholders already indicating support.
Panmure Liberum said the acquisition and equity raise were expected to be broadly neutral to earnings per share for the remainder of the current financial year, before becoming accretive from the 2028 financial year.
The broker said Landsec now had increased visibility on reaching EPRA earnings per share of around 62p by the 2030 financial year.
Brazilian state-run oil company Petrobras (PETR3.SA) said on Friday it had made a new oil discovery in ultra-deep waters off Amapa state, an area known as equatorial margin that it considers its most promising new oil frontier.
According to a securities filing, an oil-bearing interval was found in the Morpho well, marking a new discovery in block FZA-M-59, where it had already identified hydrocarbons in August.
The oil found in August was of good quality, the firm said
Petrobras CEO Magda Chambriard said last week that drilling of the first well in the region, also known as Foz do Amazonas, was expected to conclude in the coming days
Petrobras recenty announced it will drill three new wells in the area starting in January to determine wether commercial production in the environmentally-sensitive region is viable
Foz do Amazonas shares geological similarities with offshore Guyana, where ExxonMobil (XOM.N) is developing huge fields
Chambriard will hold a press conference later on Friday to detail the oil discovery, according to Petrobras
Applied Digital spustila dalších 75 MW AI infrastruktury v Polaris Forge 1, čímž zvýšila plně provozní kapacitu kampusu na 250 MW. Celý areál má mít po dokončení kapacitu 400 MW.
Completion of three additional 25 MW data halls brings fully operational capacity at Polaris Forge 1 to 250 MW | Source: Applied Digital Corporation
DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a U.S. based designer, developer, owner and operator of large-scale, purpose-built data centers engineered to support high-performance computing (“HPC”) workloads, including artificial intelligence (“AI”), machine learning, and other accelerated-compute applications, today announced it has achieved Ready for Service for the second phase of Building 2 at its Polaris Forge 1 campus, delivering an additional 75 MW of critical IT load across three 25 MW data halls.
The milestone completes Building 2’s full 150 MW of critical IT load and brings fully operational critical IT load at Polaris Forge 1 to 250 MW. The fully leased AI Factory Campus is contracted to deliver 400 MW of critical IT load at full buildout.
“Bringing another 75 MW of AI infrastructure online at Polaris Forge 1 further demonstrates our ability to turn large-scale power into operational AI infrastructure,” said Wes Cummins, Chairman and Chief Executive Officer of Applied Digital. “Securing power is only the starting point. The real work is designing, building, commissioning, and operating the infrastructure that transforms those megawatts into usable capacity for customers. That is the capability we continue to scale across our platform.”
The latest delivery follows the first 100 MW building at Polaris Forge 1 and the initial 75 MW phase of Building 2. With 250 MW now operational, Polaris Forge 1 reflects Applied Digital’s repeatable approach to developing and operating large-scale infrastructure purpose-built for advanced AI and high-performance computing workloads.
Polaris Forge 1 is located in Ellendale, North Dakota, where Applied Digital has operated since 2021 and built long-standing relationships with local leaders, partners, and community stakeholders. As the campus continues to expand, the Company remains focused on responsible development, local partnership, and creating long-term value in the communities where it builds.
About Applied Digital
Applied Digital (Nasdaq: APLD) — named Best Data Center in the Americas 2025 by Datacloud — designs, builds, and operates high-performance, sustainably engineered data centers and colocation services for artificial intelligence, cloud, networking, and blockchain workloads. Headquartered in Dallas, TX, and founded in 2021, the company combines hyperscale expertise, closed-loop cooling, and rapid deployment capabilities to deliver secure, scalable compute at industry-leading speed and efficiency, while creating economic opportunities in underserved communities through its AI Factory franchise model.
Learn more at applieddigital.com or follow @APLDdigital on X and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position, business strategy and objectives, and future financing plans. These statements use words, and variations of words, such as “will,” “continue,” “build,” “future,” “increase,” “drive,” “believe,” “look,” “ahead,” “confident,” “proven,” “deliver,” “outlook,” “expect,” “project” and “predict.” Other examples of forward-looking statements may include, but are not limited to, (i) statements that reflect perspectives and expectations regarding lease agreements and any current or prospective data center campus development; (ii) statements about the high-performance computing (HPC) industry; (iii) statements of company plans and objectives, including the company’s evolving business model, or estimates or predictions of actions by suppliers; (iv) statements of future economic performance; and (v) statements of assumptions underlying other statements and statements about the company or its business. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the company’s expectations and projections. These risks, uncertainties, and other factors include, among others: whether or not our customers exercise the renewal options under their leases with us (if not, we will not recognize further revenue from such customer under its respective lease); our ability to complete construction of our data center campuses as planned; the lead time of customer acquisition and leasing decisions and related internal approval processes; changes to artificial intelligence and HPC infrastructure needs and their impact on future plans; costs related to the HPC operations and strategy; our ability to timely deliver any services required in connection with completion of installation under lease agreements; our ability to raise additional capital to fund the ongoing datacenter construction and operations; our ability to obtain financing of datacenter leases and more broadly for our development and general corporate activities; our dependence on principal customers, including our ability to execute and perform our obligations under our leases with key customers; our ability to timely and successfully build new hosting facilities with the appropriate contractual margins and efficiencies; power or other supply disruptions and equipment failures; the inability to comply with regulations, developments and changes in regulations; cash flow and access to capital; availability of financing to continue to grow our business; decline in demand for our products and services; maintenance of third party relationships; and conditions in the debt and equity capital markets. A further list and description of these risks, uncertainties, and other factors can be found in the company’s most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, including in the sections captioned “Forward-Looking Statements” and “Risk Factors,” and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, on the company’s website (www.applieddigital.com) under “Investors,” or on request from the company. Information in this press release is as of the dates and time periods indicated herein, and the company does not undertake to update any of the information contained in these materials, except as required by law.
